Trait	n
Body mass index	1780
Insomnia	565
Type 2 diabetes	553
Total cholesterol levels	473
Low density lipoprotein cholesterol levels	453
Triglyceride levels	435
High density lipoprotein cholesterol levels	429
Inguinal hernia	388
Blood protein levels	373
Triglycerides	369
Serum metabolite ratios in chronic kidney disease	364
Neuroticism	343
Schizophrenia	318
Educational attainment	315
Educational attainment (years of education)	313
Body fat percentage	275
Intelligence (MTAG)	271
Height	267
General cognitive ability	250
Major depressive disorder or stress-related disorder	247
Systolic blood pressure	247
C-reactive protein levels	246
Serum metabolite levels	235
Waist-hip ratio	233
Alzheimer's disease	222
Sex hormone-binding globulin levels	213
Diastolic blood pressure	210
Intelligence	210
Breast cancer	196
Electrocardiogram morphology (amplitude at temporal datapoints)	189
Red blood cell count	186
Attention deficit hyperactivity disorder or autism spectrum disorder or intelligence (pleiotropy)	185
Platelet count	185
Urate levels	185
Serum metabolite levels (CMS)	183
Waist-to-hip ratio adjusted for BMI	178
Waist circumference	171
HDL cholesterol levels	168
Red cell distribution width	167
Alcohol consumption (drinks per week)	166
Waist circumference adjusted for body mass index	165
White blood cell count	164
Metabolite levels	159
Body mass index (joint analysis main effects and physical activity interaction)	152
Coronary artery disease	152
Heel bone mineral density	148
Household income (MTAG)	147
HDL cholesterol	142
Sleep duration	141
Body mass index in physically active individuals	136
Hip circumference adjusted for BMI	131
Educational attainment (MTAG)	130
Smoking initiation (ever regular vs never regular)	130
Brain morphology (MOSTest)	128
Appendicular lean mass	121
Alcohol consumption (drinks per week) (MTAG)	120
Depression	117
Fatty acid(20:4)_[M-H]1- levels	115
Hematocrit	115
Hip circumference	114
Neutrophil count	114
Estimated glomerular filtration rate	113
circulating leptin levels	112
Obesity	111
Alanine aminotransferase levels	110
Weight	110
Fatty acid(22:4)_[M-H]1- levels	109
Fatty acid(22:5)_[M-H]1- levels	109
Highest math class taken (MTAG)	108
Cerebral amyloid deposition (PET imaging)	107
Adult body size	106
Cognitive aspects of educational attainment	105
Mean corpuscular hemoglobin	105
Cortical surface area	104
Alzheimer's disease or educational attainment (pleiotropy)	103
Mean corpuscular volume	103
Brain region volumes	102
LDL cholesterol levels	102
Waist-hip index	101
Pulse pressure	100
Serum alkaline phosphatase levels	99
LDL cholesterol	98
Apolipoprotein A1 levels	97
Smoking initiation (ever regular vs never regular) (MTAG)	97
Eosinophil counts	96
General factor of neuroticism	95
Hand grip strength	92
Daytime nap	91
Smoking status (ever vs never smokers)	91
Total testosterone levels	91
Post bronchodilator FEV1	90
Schizophrenia (MTAG)	89
Externalizing behaviour (multivariate analysis)	87
Lung function (FVC)	87
Menarche (age at onset)	87
Endometriosis or asthma (pleiotropy)	86
Alcohol consumption	84
Cholesteryl ester(20:4)_[M+NH4]1+ levels	84
Cholesteryl ester(20:5)_[M+NH4]1+ levels	84
Fat-free mass	84
Lysophosphatidylcholine(20:4)_[M+H]1+ levels	84
Parkinson's disease	84
Phosphatidate(43:4)_[M-H]1- levels	84
Phosphatidylcholine-O(36:3)_M+H]1+/Phosphatidylcholine-P(36:2)_M+H]1+ levels	84
Phosphatidylcholine-O(36:5)_[M+H]1+/Phosphatidylcholine-P(36:4)_[M+H]1+ levels	84
Phosphatidylcholine-O(38:5)_[M+H]1+/Phosphatidylcholine-P(38:4)_[M+H]1+ levels	84
Phosphatidylcholine-O(40:5)_[M+H]1+/Phosphatidylcholine-P(40:4)_[M+H]1+ levels	84
Phosphatidylcholine(33:2)_[M+H]1+/Phosphatidylethanolamine(36:2)_[M+H]1+/Phosphatidate(38:3)_[M+NH4]1+ levels	84
Phosphatidylcholine(35:4)_[M+H]1+/Phosphatidylethanolamine(38:4)_[M+H]1+/Phosphatidate(40:5)_[M+NH4]1+ levels	84
Phosphatidylcholine(36:3)_[M+H]1+/Phosphatidylethanolamine(39:3)_[M+H]1+/Phosphatidate(41:4)_[M+NH4]1+ levels	84
Phosphatidylcholine(36:3)_[M+OAc]1-/Phosphatidylserine(40:2)_[M-H]1- levels	84
Phosphatidylcholine(36:5)_[M+OAc]1-/Phosphatidylserine(40:4)_[M-H]1- levels	84
Phosphatidylcholine(37:4)_[M+H]1+/Phosphatidylethanolamine(40:3)_[M+H]1+ levels	84
Phosphatidylcholine(37:4)_[M+H]1+/Phosphatidylethanolamine(40:4)_[M+H]1+/Phosphatidate(42:5)_[M+NH4]1+ levels	84
Phosphatidylcholine(38:3)_[M+H]1+/Phosphatidylethanolamine(41:3)_[M+H]1+/Phosphatidate(43:4)_[M+NH4]1+ levels	84
Phosphatidylcholine(38:3)_[M+OAc]1-/Phosphatidylserine(42:2)_[M-H]1- levels	84
Phosphatidylcholine(38:4)_[M+H]1+/Phosphatidylethanolamine(41:4)_[M+H]1+ levels	84
Phosphatidylcholine(38:4)_[M+OAc]1-/Phosphatidylserine(42:3)_[M-H]1- levels	84
Phosphatidylcholine(38:5)_[M+H]1+/Phosphatidylethanolamine(41:5)_[M+H]1+/Phosphatidate(43:6)_[M+NH4]1+ levels	84
Phosphatidylcholine(40:5)_[M+H]1+ levels	84
Phosphatidylcholine(40:5)_[M+OAc]1-/Phosphatidylserine(44:4)_[M-H]1- levels	84
Phosphatidylcholine(42:4)_[M+OAc]1- levels	84
Phosphatidylethanolamine-O(38:4)_[M-H]1-/Phosphatidylcholine-O(35:4)_[M-H]1-/Phosphatidylcholine-P(35:3)_[M-H]1- levels	84
Phosphatidylethanolamine(34:2)_[M+H]1+ levels	84
Phosphatidylethanolamine(38:5)_[M-H]1- levels	84
Phosphatidylglycerol(36:0)_[M-H]1- levels	84
Phosphatidylinositol(36:1)_[M+OAc]1- levels	84
Phosphatidylinositol(38:4)_[M-H]1- levels	84
Sphingomyelin(44:9)_[M+H]1- levels	84
Cognitive performance (MTAG)	83
Cortical thickness	83
Mean platelet volume	83
Phosphatidate(41:2)_[M+H]1+ levels	83
Predicted visceral adipose tissue	83
A body shape index	82
BMI (adjusted for smoking behaviour)	82
Estimated glomerular filtration rate (creatinine)	82
Phosphatidylethanolamine-O(38:6)_[M+H]1+/Phosphatidylcholine-P(35:5)_[M+H]1+ levels	82
Phosphatidylinositol-O(36:0)_[M-H]1-/Phosphatidylglycerol(37:0)_[M+OAc]1- levels	82
Phosphatidylserine(44:6)_[M+OAc]1- levels	82
Cholesteryl ester(18:3)_[M+NH4]1+ levels	81
Fish- and plant-related diet	81
Phosphatidate(39:1)_[M+H]1+ levels	81
Phosphatidylcholine-O(40:6)_[M+H]1+/Phosphatidylcholine-P(40:5)_[M+H]1+ levels	81
Phosphatidylcholine(32:0)_[M+H]1+/Phosphatidylethanolamine(35:0)_[M+H]1+/Phosphatidate(37:1)_[M+NH4]1+ levels	81
Phosphatidylcholine(33:3)_[M+H]1+/Phosphatidylethanolamine(36:3)_[M+H]1+/Phosphatidate(38:4)_[M+NH4]1+ levels	81
Phosphatidylcholine(40:4)_[M+OAc]1-/Phosphatidylserine(44:3)_[M-H]1- levels	81
Phosphatidylglycerol(34:0)_[M-H]1- levels	81
Phosphatidylserine(42:7)_[M+OAc]1- levels	81
Self-reported math ability (MTAG)	81
Vertex-wise cortical thickness	80
Alcohol use disorder (consumption score)	79
Triacylglycerol(56:6)_[M+NH4]1+ levels	79
Lymphocyte count	78
Phosphatidylcholine(34:2)_[M+H]1+/Phosphatidylethanolamine(37:2)_[M+H]1+/Phosphatidate(39:3)_[M+NH4]1+ levels	78
Phosphatidylinositol(36:2)_[M-H]1- levels	78
Phosphatidylinositol(36:4)_[M-H]1- levels	78
Post bronchodilator FEV1/FVC ratio	78
Triacylglycerol(56:4)_[M+NH4]1+ levels	78
Triacylglycerol(56:7)_[M+NH4]1+ levels	78
Triacylglycerol(58:9)_[M+NH4]1+ levels	78
Blood urea nitrogen levels	77
Hemoglobin levels	77
Neurociticism	77
Leisure sedentary behaviour (television watching)	76
Phosphatidylinositol(36:0)_[M+OAc]1- levels	76
Phosphatidylserine(35:2)_[M+OAc]1- levels	76
Vertex-wise sulcal depth	76
Body mass index (joint analysis main effects and smoking interaction)	75
Phosphatidylcholine(40:6)_[M+H]1+/Phosphatidylethanolamine(43:6)_[M+H]1+ levels	74
Risk-taking behavior (multivariate analysis)	74
Non-HDL cholesterol levels	73
Smoking initiation	73
Apolipoprotein B levels	71
BMI in non-smokers	70
Phosphatidylcholine(36:2)_[M+H]1+/Phosphatidylethanolamine(39:2)_[M+H]1+/Phosphatidate(41:3)_[M+NH4]1+ levels	70
Aspartate aminotransferase levels	69
Depressed affect	69
Phosphatidylserine(42:5)_[M+OAc]1- levels	69
Body mass index in physically inactive individuals	68
Hemoglobin concentration	68
Major depressive disorder	68
Self-reported math ability	68
Coffee consumption (cups per day)	66
Phosphatidylinositol-O(33:0)_[M-H]1- levels	66
C-reactive protein	65
Serum uric acid levels	65
Walking pace	65
Coffee consumption	64
Experiencing mood swings	64
Household income	64
Phosphatidylinositol(34:2)_[M-H]1- levels	64
Serum 25-Hydroxyvitamin D levels	64
Alcohol use disorder	63
Cognitive ability, years of educational attainment or schizophrenia (pleiotropy)	63
Monocyte count	63
Vertex-wise cortical surface area	63
Cognitive performance	62
Depressive symptoms	62
Worry	62
Morning person	61
Glycated hemoglobin levels	60
Highest math class taken	60
Medication use (agents acting on the renin-angiotensin system)	60
Metabolic syndrome	60
Serum albumin levels	60
Phosphatidylcholine(35:3)_[M+H]1+/Phosphatidylethanolamine(38:3)_[M+H]1+/Phosphatidate(40:4)_[M+NH4]1+ levels	59
Age of smoking initiation (MTAG)	58
Cholesteryl ester(16:0)_[M+NH4]1+ levels	58
Childhood body mass index	57
Crohn's disease	57
Metabolic biomarkers (multivariate analysis)	57
Body fat distribution (arm fat ratio)	56
Sex hormone-binding globulin levels adjusted for BMI	55
Urinary sodium excretion	55
Hemoglobin	54
Phosphatidylcholine(40:6)_[M+OAc]1-/Phosphatidylserine(44:5)_[M-H]1- levels	54
Trans fatty acid levels	54
White matter microstructure (mean diusivities)	54
Smoking status	53
White matter microstructure (axial diusivities)	53
Body size at age 10	52
Diacylglycerol(36:3)_[M+H-H2O]1+ levels	52
Glycerophospholipid levels	52
Multisite chronic pain	52
Whole brain restricted isotropic diffusion (multivariate analysis)	52
Irritable mood	51
Albumin levels	50
Diacylglycerol(36:2)_[M+H-H2O]1+ levels	50
Mean corpuscular hemoglobin concentration	50
Number of sexual partners	50
Phosphatidylcholine(38:6)_[M+H]1+/Phosphatidylethanolamine(41:6)_[M+H]1+ levels	50
Problematic alcohol use (MTAG)	50
Triacylglycerol(54:3)_[M+NH4]1+ levels	50
Whole brain restricted directional diffusion (multivariate analysis)	50
Cerebrospinal fluid AB1-42 levels	49
Dietary macronutrient intake (multi-trait analysis)	48
Feeling worry	48
Noncognitive aspects of educational attainment	48
Urinary albumin-to-creatinine ratio	48
Waist-to-hip ratio adjusted for BMI (additive genetic model)	48
White matter microstructure (radial diusivities)	48
Age at first sexual intercourse	47
Lifetime smoking	47
Male-pattern baldness	47
Medication use (drugs used in diabetes)	46
Plateletcrit	46
Bipolar disorder	45
Common executive function	45
Risk-taking tendency (4-domain principal component model)	45
Systemic lupus erythematosus	45
Alzheimer's disease biomarkers	44
Snoring	44
Calcium levels	43
Cognitive ability	43
Creatinine levels	43
Reaction time	43
Aerodigestive squamous cell cancer (pleiotropy)	42
Anorexia nervosa, attention-deficit/hyperactivity disorder, autism spectrum disorder, bipolar disorder, major depression, obsessive-compulsive disorder, schizophrenia, or Tourette syndrome (pleiotropy)	42
Autism spectrum disorder or schizophrenia	42
Bipolar disorder (MTAG)	42
Bitter alcoholic beverage consumption	42
Cystatin C levels	42
Depression (broad)	42
Lung cancer	42
Mean arterial pressure x alcohol consumption interaction (2df test)	42
Phosphatidate(34:2)_[M-H]1- levels	42
Phosphatidylglycerol(35:3)_[M-H]1- levels	42
Refractive error	42
Serum total protein level	42
Smoking cessation (MTAG)	42
Squamous cell lung carcinoma	42
White matter microstructure (fractional anisotropy)	42
Asthma	41
Chronotype	41
Feeling miserable	41
General risk tolerance (MTAG)	41
Leisure screen time	41
Medication use (diuretics)	41
Myocardial infarction	41
Well-being spectrum (multivariate analysis)	41
Blood metabolite levels	40
Diacylglycerol_38:5_[M+H-H2O]1+ levels	40
Feeling nervous	40
Phosphatidylcholine-O(38:4)_[M+H]1+/Phosphatidylcholine-P(38:3)_[M+H]1+ levels	40
Triacylglycerol_56:6_[M+NH4]1+ levels	40
Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)	40
HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)	39
Hemoglobin A1c levels	39
Lifetime smoking index	39
Mean arterial pressure	39
Cholesterol, total	38
Longevity	38
Lung cancer in ever smokers	38
Phosphatidylcholine levels	38
Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)	38
Bioavailable testosterone levels	37
Body fat distribution (trunk fat ratio)	37
Cognitive ability (MTAG)	37
Diacylglycerol_38:6_[M+H-H2O]1+ levels	37
Fruit consumption	37
Gastroesophageal reflux disease	37
HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)	37
High light scatter reticulocyte count	37
Liver enzyme levels (alkaline phosphatase)	37
Nonalcoholic fatty liver disease	37
Positive affect	37
Triacylglycerol_56:5_[M+NH4]1+ levels	37
Triglyceride levels in current drinkers	37
Whole brain free water diffusion (multivariate analysis)	37
Biological sex	36
Medication use (HMG CoA reductase inhibitors)	36
Smoking behaviour (cigarettes smoked per day)	36
Tea consumption	36
BMI in smokers	35
Cerebrospinal fluid t-tau:AB1-42 ratio	35
Cigarettes smoked per day (MTAG)	35
Lifetime smoking (without educational attainment)	35
Mean spheric corpuscular volume	35
Morningness	35
Reticulocyte count	35
Aspartate aminotransferase to alanine aminotransferase ratio	34
Cardiovascular disease	34
Cholesteryl ester_16:0_[M+NH4]1+ levels	34
Cholesteryl ester_18:3_[M+NH4]1+ levels	34
F-acquired taste liking (derived food-liking factor)	34
Fasting glucose	34
Lung function (FEV1)	34
Obesity (early onset extreme)	34
Problematic alcohol use	34
Systolic blood pressure x alcohol consumption interaction (2df test)	34
Verbal declarative memory	34
Alcohol dependence	33
Cholesteryl ester_20:3_[M+NH4]1+ levels	33
Inflammatory bowel disease	33
Phosphatidylcholine_32:0_[M+H]1+/Phosphatidylethanolamine_35:0_[M+H]1+/Phosphatidate_37:1_[M+NH4]1+ levels	33
Platelet distribution width	33
Triacylglycerol_56:7_[M+NH4]1+ levels	33
Verbal-numerical reasoning	33
Cholesteryl ester_18:2_[M+NH4]1+ levels	32
Feeling fed-up	32
Gamma glutamyl transpeptidase	32
Phosphatidate(40:5)_[M+OAc]1-/Phosphatidylglycerol(39:5)_[M-H]1- levels	32
Phosphatidylcholine(39:6)_[M+OAc]1-/Phosphatidylserine(43:5)_[M-H]1- levels	32
Subcortical volume (MOSTest)	32
Triacylglycerol_52:6_[M+NH4]1+ levels	32
Age at first birth	31
Body mass index (adult)	31
Cholesteryl ester_20:5_[M+NH4]1+ levels	31
Cholesteryl ester_22:6_[M+NH4]1+ levels	31
Chronic elevation of alanine aminotransferase (cALT) levels	31
Diacylglycerol_36:3_[M+H-H2O]1+ levels	31
Diacylglycerol_38:3_[M+H-H2O]1+ levels	31
Diacylglycerol_38:4_[M+H-H2O]1+ levels	31
Fasting insulin	31
Feeling guilty	31
Lysophosphatidylcholine_20:4_[M+H]1+ levels	31
Lysophosphatidylethanolamine_18:2_[M-H]1- levels	31
Lysophosphatidylethanolamine_20:4_[M-H]1- levels	31
Lysophosphatidylethanolamine_22:4_[M-H]1- levels	31
Meat-related diet	31
Medication use (calcium channel blockers)	31
Mental health study participation (completed survey)	31
Obesity (extreme)	31
Phosphatidylcholine_31:2_[M+H]1+/Phosphatidylethanolamine_34:2_[M+H]1+/Phosphatidate_36:3_[M+NH4]1+ levels	31
Phosphatidylcholine_32:2_[M+H]1+/Phosphatidylethanolamine_35:2_[M+H]1+/Phosphatidate_37:3_[M+NH4]1+ levels	31
Phosphatidylcholine_34:2_[M+H]1+/Phosphatidylethanolamine_37:2_[M+H]1+/Phosphatidate_39:3_[M+NH4]1+ levels	31
Phosphatidylcholine_34:2_[M+OAc]1-/Phosphatidylserine_38:1_[M-H]1- levels	31
Phosphatidylcholine_34:3_[M+H]1+/Phosphatidylethanolamine_37:3_[M+H]1+/Phosphatidate_39:4_[M+NH4]1+ levels	31
Phosphatidylcholine_35:2_[M+H]1+/Phosphatidylethanolamine_38:2_[M+H]1+/Phosphatidate_40:3_[M+NH4]1+ levels	31
Phosphatidylcholine_35:3_[M+H]1+/Phosphatidylethanolamine_38:3_[M+H]1+/Phosphatidate_40:4_[M+NH4]1+ levels	31
Phosphatidylcholine_35:4_[M+H]1+/Phosphatidylethanolamine_38:4_[M+H]1+/Phosphatidate_40:5_[M+NH4]1+ levels	31
Phosphatidylcholine_36:2_[M+OAc]1-/Phosphatidylserine_40:1_[M-H]1- levels	31
Phosphatidylcholine_36:3_[M+H]1+/Phosphatidylethanolamine_39:3_[M+H]1+/Phosphatidate_41:4_[M+NH4]1+ levels	31
Phosphatidylcholine_37:3_[M+OAc]1-/Phosphatidylserine_41:2_[M-H]1- levels	31
Phosphatidylcholine_37:4_[M+H]1+/Phosphatidylethanolamine_40:4_[M+H]1+/Phosphatidate_42:5_[M+NH4]1+ levels	31
Phosphatidylcholine_38:3_[M+H]1+/Phosphatidylethanolamine_41:3_[M+H]1+/Phosphatidate_43:4_[M+NH4]1+ levels	31
Phosphatidylcholine_38:5_[M+H]1+/Phosphatidylethanolamine_41:5_[M+H]1+/Phosphatidate_43:6_[M+NH4]1+ levels	31
Phosphatidylcholine_40:4_[M+H]1+/Phosphatidylethanolamine_43:4_[M+H]1+ levels	31
Phosphatidylcholine_40:5_[M+H]1+ levels	31
Phosphatidylcholine_40:7_[M+H]1+ levels	31
Phosphatidylcholine_42:4_[M+OAc]1- levels	31
Phosphatidylcholine-O_36:4_[M+H]1+/Phosphatidylcholine-P_36:3_[M+H]1+ levels	31
Phosphatidylcholine-O_38:5_[M+H]1+/Phosphatidylcholine-P_38:4_[M+H]1+ levels	31
Phosphatidylcholine-O_40:5_[M+H]1+/Phosphatidylcholine-P_40:4_[M+H]1+ levels	31
Phosphatidylcholine-O_44:5_[M+H]1+/Phosphatidylcholine-P_44:4_[M+H]1+ levels	31
Phosphatidylcholine-O_44:5_[M+OAc]1-/Phosphatidylcholine-P_44:4_[M+OAc]1- levels	31
Phosphatidylethanolamine_34:2_[M-H]1- levels	31
Phosphatidylethanolamine_35:2_[M-H]1- levels	31
Phosphatidylethanolamine_36:2_[M-H]1- levels	31
Phosphatidylethanolamine_36:3_[M-H]1- levels	31
Phosphatidylethanolamine_37:2_[M-H]1- levels	31
Phosphatidylethanolamine_38:2_[M-H]1- levels	31
Phosphatidylethanolamine_38:3_[M-H]1- levels	31
Phosphatidylethanolamine_38:4_[M-H]1- levels	31
Phosphatidylethanolamine_38:5_[M-H]1- levels	31
Phosphatidylethanolamine_39:4_[M-H]1- levels	31
Phosphatidylethanolamine-O_34:3_[M-H]1-/Phosphatidylethanolamine-P_34:2_[M-H]1- levels	31
Phosphatidylethanolamine-O_36:5_[M-H]1-/Phosphatidylethanolamine-P_36:4_[M-H]1- levels	31
Phosphatidylethanolamine-O_38:3_[M-H]1-/Phosphatidylethanolamine-P_38:2_[M-H]1- levels	31
Phosphatidylethanolamine-O_38:5_[M-H]1-/Phosphatidylethanolamine-P_38:4_[M-H]1- levels	31
Phosphatidylethanolamine-O_40:5_[M-H]1-/Phosphatidylethanolamine-P_40:4_[M-H]1- levels	31
Phosphatidylglycerol_35:3_[M-H]1- levels	31
Phosphatidylinositol_34:0_[M+H]1+ levels	31
Phosphatidylinositol_36:2_[M-H]1- levels	31
Phosphatidylinositol_36:3_[M-H]1- levels	31
Phosphatidylinositol_38:4_[M-H]1- levels	31
Phosphatidylinositol-O_36:0_[M-H]1- levels	31
Phosphatidylserine_40:5_[M+H]1+/Phosphatidylglycerol_40:7_[M+NH4]1+ levels	31
Sphingomyelin_34:2_[M+H]1+ levels	31
Sphingomyelin_36:2_[M+H]1+ levels	31
Subjective well-being	31
Total bilirubin levels	31
Triacylglycerol_56:8_[M+NH4]1+ levels	31
Triacylglycerol_58:10_[M+NH4]1+ levels	31
Triacylglycerol_58:7_[M+NH4]1+ levels	31
Triacylglycerol_58:9_[M+NH4]1+ levels	31
Depressive symptoms (MTAG)	30
Dietary macronutrient intake	30
Disruptive behavior (multivariate analysis)	30
Gout	30
Lysophosphatidylcholine_22:6_[M+H]1+ levels	30
Lysophosphatidylcholine-O_16:1_[M+H]1+/Lysophosphatidylcholine-P_16:0_[M+H]1+ levels	30
Phosphatidylcholine_32:0_[M+OAc]1- levels	30
Phosphatidylcholine_34:4_[M+H]1+/Phosphatidylethanolamine_37:4_[M+H]1+/Phosphatidate_39:5_[M+NH4]1+ levels	30
Phosphatidylcholine_37:5_[M+H]1+/Phosphatidylethanolamine_40:5_[M+H]1+/Phosphatidate_42:6_[M+NH4]1+ levels	30
Phosphatidylcholine_38:2_[M+H]1+/Phosphatidylethanolamine_41:2_[M+H]1+ levels	30
Phosphatidylcholine_40:6_[M+H]1+/Phosphatidylethanolamine_43:6_[M+H]1+ levels	30
Phosphatidylcholine_40:6_[M+OAc]1-/Phosphatidylserine_44:5_[M-H]1- levels	30
Phosphatidylcholine-O_42:6_[M+OAc]1-/Phosphatidylcholine-P_42:5_[M+OAc]1- levels	30
Phosphatidylethanolamine_37:3_[M-H]1- levels	30
Phosphatidylinositol_34:2_[M-H]1- levels	30
Phosphatidylinositol_38:0_[M-H]1- levels	30
Phosphatidylserine_40:3_[M+H]1+/Phosphatidylglycerol_40:5_[M+NH4]1+ levels	30
Pork consumption	30
Alzheimer’s disease polygenic risk score (upper quantile vs lower quantile)	29
Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) to 1,3,7-trimethylxanthine (caffeine) ratio)	29
Oily fish consumption	29
Phosphatidylcholine_35:5_[M+OAc]1-/Phosphatidylserine_39:4_[M-H]1- levels	29
Phosphatidylcholine_44:5_[M+OAc]1- levels	29
Phosphatidylethanolamine-O_36:4_[M-H]1-/Phosphatidylethanolamine-P_36:3_[M-H]1- levels	29
Phosphatidylethanolamine-O_38:6_[M-H]1-/Phosphatidylethanolamine-P_38:5_[M-H]1- levels	29
Phosphatidylethanolamine-O_40:6_[M-H]1-/Phosphatidylethanolamine-P_40:5_[M-H]1- levels	29
Phosphatidylglycerol_34:0_[M-H]1- levels	29
Phosphatidylglycerol_36:0_[M-H]1- levels	29
Phosphatidylinositol_36:4_[M-H]1- levels	29
Phosphatidylserine-P_42:1_[M+H]1+/Phosphatidylglycerol-P_42:6_[M+NH4]1+ levels	29
Triacylglycerol_56:4_[M+NH4]1+ levels	29
Caffeine consumption from tea	28
Cognitive traits (MTAG)	28
Educational attainment (college completion)	28
Eosinophil percentage of white cells	28
Fatty acid(18:4)_[M-H]1- levels	28
Linoleic acid levels	28
Liver enzyme levels (gamma-glutamyl transferase)	28
Lung function (FEV1/FVC)	28
Lysophosphatidylethanolamine-O_18:1_[M-H]1-/Lysophosphatidylethanolamine-P_18:0_[M-H]1- levels	28
Neuritic plaque	28
Neurofibrillary tangles	28
Obesity-related traits	28
Phosphatidylcholine_36:5_[M+H]1+/Phosphatidylethanolamine_39:5_[M+H]1+/Phosphatidate_41:6_[M+NH4]1+ levels	28
Phosphatidylcholine_38:6_[M+H]1+/Phosphatidylethanolamine_41:6_[M+H]1+ levels	28
Phosphatidylcholine_52:4_[M+OAc]1- levels	28
Phosphatidylcholine-O_35:4_[M+OAc]1-/Phosphatidylcholine-P_35:3_[M+OAc]1- levels	28
Phosphatidylcholine-O_38:4_[M+H]1+/Phosphatidylcholine-P_38:3_[M+H]1+ levels	28
Phosphatidylcholine-O_40:6_[M+H]1+/Phosphatidylcholine-P_40:5_[M+H]1+ levels	28
Phosphatidylethanolamine-O_36:3_[M-H]1-/Phosphatidylethanolamine-P_36:2_[M-H]1- levels	28
Phosphatidylinositol_36:2_[M+H]1+ levels	28
Smoking cessation	28
Type 1 diabetes	28
Adventurousness	27
Body fat distribution (leg fat ratio)	27
Chronic obstructive pulmonary disease	27
Cortical surface area (MOSTest)	27
HDL cholesterol levels in current drinkers	27
Mean reticulocyte volume	27
Medication use (beta blocking agents)	27
Osteoarthritis	27
Pulse pressure x alcohol consumption interaction (2df test)	27
Relative carbohydrate intake	27
Triacylglycerol_58:8_[M+NH4]1+ levels	27
Urea levels	27
Cholesteryl ester_22:5_[M+NH4]1+ levels	26
Diacylglycerol_36:2_[M+H-H2O]1+ levels	26
Fatty acid(22:6)_[M-H]1- levels	26
Major depressive disorder (MTAG)	26
Phosphatidylethanolamine_34:0_[M-H]1- levels	26
Phosphatidylethanolamine_40:6_[M-H]1- levels	26
Physical activity	26
Spherical equivalent	26
Testosterone levels	26
Triacylglycerol_54:7_[M+NH4]1+ levels	26
Word reading	26
Acceptance of an invitation to participate in a mental health questionnaire	25
Age-related diseases, mortality and associated endophenotypes	25
Age-related macular degeneration	25
Alcohol consumption (drinks per month) (UKB data field 1578, 4424)	25
Cancer (pleiotropy)	25
Feeling hurt	25
LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)	25
Life satisfaction	25
Participation in an health questionnaire (not invited vs invited)	25
Relative fat intake	25
Worry too long after an embarrassing experience	25
Age-related disease endophenotypes	24
Colorectal cancer	24
Feeling tense	24
Phosphatidate_34:2_[M-H]1- levels	24
Principal component-derived dietary pattern 1	24
Sleep duration (short sleep)	24
Cerebrospinal fluid t-tau levels	23
Diastolic blood pressure x alcohol consumption interaction (2df test)	23
F-fish liking (derived food-liking factor)	23
High light scatter reticulocyte percentage of red cells	23
LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)	23
Mental health study participation (provided email address)	23
Parental longevity (mother's age at death or mother's attained age)	23
Serum creatinine levels	23
Sphingomyelin_38:2_[M+H]1+ levels	23
Alzheimer's disease or gastroesophageal reflux disease	22
Bipolar disorder or major depressive disorder	22
C-reactive protein levels or HDL-cholesterol levels (pleiotropy)	22
Circulating docosahexaenoic acid levels	22
circulating leptin levels adjusted for BMI	22
Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test)	22
Diastolic blood pressure x smoking status (ever vs never) interaction (2df test)	22
Hypertension	22
Liver enzyme levels (alanine transaminase)	22
Serum metabolite concentrations in chronic kidney disease	22
Systolic blood pressure x smoking status (current vs non-current) interaction (2df test)	22
Systolic blood pressure x smoking status (ever vs never) interaction (2df test)	22
Alcohol consumption (heavy vs. light/non-drinkers)	21
Automobile speeding propensity	21
Average diameter for HDL particles	21
Brain morphology (min-P)	21
Ease of getting up in the morning	21
F-sharp flavour liking (derived food-liking factor)	21
Fasting blood glucose	21
Herring liking	21
Medication use (antithrombotic agents)	21
Opioid use disorder (MTAG)	21
Ratio of monounsaturated fatty acids to total fatty acids	21
Resting heart rate	21
Alcohol use disorder (total score)	20
Asthma and cardiovascular disease	20
Cholesteryl ester_14:0_[M+NH4]1+ levels	20
Decaffeinated coffee consumption or major depression disorder	20
F-savoury food liking (derived food-liking factor)	20
F-seafood liking (derived food-liking factor)	20
F-small fish liking (derived food-liking factor)	20
Glycine levels	20
Gut microbiota (bacterial taxa)	20
Hip index	20
Liver liking	20
Macular thickness	20
Monounsaturated fatty acid levels	20
Neuroticism conditioned on Townsend deprivation index (multi-trait conditioning and joint analysis)	20
Phosphatidylcholine-O_33:3_[M+H]1+/Phosphatidylcholine-P_33:2_[M+H]1+/Phosphatidylethanolamine-O_36:3_[M+H]1+ levels	20
Phosphatidylinositol_35:2_[M-H]1- levels	20
Protein quantitative trait loci (liver)	20
QT interval	20
Reticulocyte fraction of red cells	20
Total lipid levels in HDL	20
Apolipoprotein E (isoform E2) levels	19
Apolipoprotein E (isoform E3) levels	19
Brain shape (segment 1)	19
Caffeine consumption from coffee or tea	19
Cholesteryl ester levels in medium HDL	19
Cognitive function	19
Coronary heart disease	19
F-fatty food liking (derived food-liking factor)	19
F-fatty/salty food liking (derived food-liking factor)	19
Fatty acid(20:3)_[M-H]1- levels	19
Gamma glutamyl transferase levels	19
Hippocampal volume	19
Insomnia symptoms (never/rarely vs. usually)	19
Loneliness	19
Migraine	19
Osteoarthritis of the hip or knee	19
Parental longevity (father's age at death or father's attained age)	19
Parental longevity (mother's age at death)	19
Parkinson's disease or first degree relation to individual with Parkinson's disease	19
Prostate cancer	19
Rheumatoid arthritis	19
Sardines liking	19
Subcortical volume (min-P)	19
Subcutaneous adipose tissue	19
Urolithiasis	19
Anxiety	18
Bitter beverage consumption	18
Body mass index x sex x age interaction (4df test)	18
Caffeine metabolism (plasma 1,3,7-trimethylxanthine (caffeine) level)	18
Cerebrospinal fluid p-Tau181p:AB1-42 ratio	18
Cholelithiasis	18
Cholesterol levels in medium HDL	18
Cholesterol levels in very large VLDL	18
Concentration of HDL particles	18
Crisps liking	18
Decaffeinated coffee consumption and/or neuroticism	18
Dementia with Lewy bodies	18
Direct bilirubin levels	18
Docosahexaenoic acid levels	18
F-cheese liking (derived food-liking factor)	18
Free cholesterol to total lipids ratio in large HDL	18
Intraocular pressure	18
Lewy body disease	18
Multiple sclerosis	18
Neuropsychiatric disorders	18
Nicotine metabolite ratio in current smokers	18
Occupational attainment	18
Phosphatidylcholine_33:2_[M+OAc]1-/Phosphatidylserine_37:1_[M-H]1- levels	18
Phospholipid levels in large HDL	18
Phospholipids to total lipids ratio in small LDL	18
Quantitative traits	18
Sphingomyelin levels	18
Total triglycerides levels	18
Triacylglyceride levels	18
Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction)	18
White matter hyperintensity volume	18
Anxiety/tension (special factor of neuroticism)	17
Caffeine consumption from coffee	17
Cognitive impairment test score	17
Free cholesterol levels in medium HDL	17
Free cholesterol levels in very large VLDL	17
Insomnia symptoms (never/rarely vs. sometimes/usually)	17
Maximum habitual alcohol consumption	17
Medication use (thyroid preparations)	17
Mood instability	17
Neuroticism conditioned on self-rated math ability (multi-trait conditioning and joint analysis)	17
Parental longevity (combined parental attained age, Martingale residuals)	17
Phospholipids to total lipids ratio in medium HDL	17
Phospholipids to total lipids ratio in very large HDL	17
Physical activity (overall physical activity time)	17
Sense of smell	17
Sensitivity to environmental stress and adversity	17
Total lipid levels in VLDL	17
Total PHF-tau (SNP x SNP interaction)	17
Triglyceride levels in LDL	17
Triglyceride levels in medium LDL	17
White matter hyperintensity volume (adjusted for hypertension)	17
Allergic disease (asthma, hay fever or eczema)	16
Alzheimer's disease or family history of Alzheimer's disease	16
Atrial fibrillation	16
Bipolar I disorder	16
Bitter non-alcoholic beverage consumption	16
Body fat mass	16
Body mass index (age>50)	16
Brain imaging measurements	16
Breast cancer (estrogen-receptor negative)	16
Childhood obesity	16
Cholesterol levels in large HDL	16
Cholesterol levels in large VLDL	16
Cholesteryl ester levels in large HDL	16
Core binding factor acute myeloid leukemia	16
Degree of unsaturation	16
Extremely high intelligence	16
F-savour/caloric food liking (derived food-liking factor)	16
FEV1	16
Fibrinogen levels	16
Free cholesterol levels in large VLDL	16
Free testosterone levels	16
Hip circumference variance	16
Hypothyroidism	16
Immature fraction of reticulocytes	16
LDL cholesterol levels in current drinkers	16
Lean body mass	16
Lipid metabolism phenotypes	16
Lysophosphatidylcholine-2O_18:0_[M+H]1+ levels	16
Lysophosphatidylethanolamine-P_20:0_[M-H]1- levels	16
Male puberty timing (age at voice breaking MTAG)	16
Neck circumference	16
Neuroticism conditioned on average household income before tax (multi-trait conditioning and joint analysis)	16
Neuroticism conditioned on cognitive performance (multi-trait conditioning and joint analysis)	16
Neuroticism conditioned on educational attainment (multi-trait conditioning and joint analysis)	16
Neutrophil percentage of white cells	16
Ovarian cancer in BRCA1 mutation carriers	16
Phosphatidylinositol_35:0_[M-H]1- levels	16
Phospholipids to total lipids ratio in large VLDL	16
Psoriasis	16
Red blood cell fatty acid levels	16
Relative sugar intake	16
Shellfish liking	16
Subscapular skin fold thickness	16
Total lipid levels in large VLDL	16
Triglyceride levels in small LDL	16
Triglyceride levels in small VLDL	16
Triglyceride levels in very small VLDL	16
Ulcerative colitis	16
Verbal learning	16
Verbal short term memory (paragraph recall test)	16
Waist circumference variance	16
Adolescent idiopathic scoliosis	15
Alzheimer's disease (age of onset)	15
Autism spectrum disorder	15
Birth weight	15
BMI at 7 years old	15
BMI at 8 years old	15
Body mass index variance	15
Brain imaging	15
Cholesterol to total lipids ratio in large HDL	15
Cholesterol to total lipids ratio in medium HDL	15
Cholesteryl ester levels in chylomicrons and extremely large VLDL	15
Cholesteryl esters to total lipids ratio in large HDL	15
Cholesteryl esters to total lipids ratio in medium HDL	15
Cholesteryl esters to total lipids ratio in very small VLDL	15
Concentration of large VLDL particles	15
Concentration of medium HDL particles	15
Diastolic blood pressure x depressive symptoms interaction (2df test)	15
Eczema	15
Estimated glomerular filtration rate (cystatin c)	15
F-chocolate/coffee liking (derived food-liking factor)	15
F-deep fried food liking (derived food-liking factor)	15
Free cholesterol to total lipids ratio in large LDL	15
Free cholesterol to total lipids ratio in medium HDL	15
Free cholesterol to total lipids ratio in medium LDL	15
Fresh fruit consumption	15
Gallstone disease	15
Insulin-like growth factor 1 levels	15
Left-handedness	15
Lipoprotein (a) levels	15
Lipoprotein-associated phospholipase A2 activity and mass	15
Lymphocyte percentage of white cells	15
Monocyte percentage of white cells	15
Neuroticism conditioned on highest math class (multi-trait conditioning and joint analysis)	15
Non-albumin protein levels	15
Osteoarthrosis (time to event)	15
Parental lifespan	15
Parental longevity (combined parental age at death)	15
Phospholipid levels in large VLDL	15
Ratio of omega-6 fatty acids to omega-3 fatty acids	15
Ratio of triglycerides to phosphoglycerides	15
Saturated fatty acid levels	15
Smoked fish liking	15
Tonsillectomy	15
Total fatty acid levels	15
Total lipid levels in large HDL	15
Total lipid levels in medium HDL	15
Triglyceride levels in large LDL	15
Triglyceride levels in large VLDL	15
Triglyceride levels in medium VLDL	15
Triglycerides to total lipids ratio in very small VLDL	15
Waist circumference adjusted for BMI in active individuals	15
Blood glucose levels	14
Breast size	14
Childhood body fatness	14
Cholesterol to total lipids ratio in very small VLDL	14
Cholesteryl ester levels in large VLDL	14
Cingulate cortical amyloid beta load	14
Concentration of large HDL particles	14
Concentration of very large VLDL particles	14
Cortical thickness (MOSTest)	14
Epithelial ovarian cancer	14
Essential hypertension (time to event)	14
F-strong flavour liking (derived food-liking factor)	14
Free cholesterol levels in large HDL	14
Ideal cardiovascular health score (clinical and behavioral)	14
Lamb consumption	14
Longevity (age >90th survival percentile)	14
Longevity (age >99th survival percentile)	14
Mackerel liking	14
Moderate to vigorous physical activity levels	14
Non-oily fish consumption	14
Obese vs. thin	14
Phosphatidylcholine_39:6_[M+OAc]1- levels	14
Phosphoglycerides levels	14
Phospholipid levels in medium HDL	14
Phospholipid levels in very large VLDL	14
Phospholipids to total lipids ratio in large LDL	14
Phospholipids to total lipids ratio in medium VLDL	14
Post-traumatic stress disorder (mental health questionnaire or predicted)	14
Ratio of docosahexaenoic acid to total fatty acid levels	14
Ratio of polyunsaturated fatty acids to monounsaturated fatty acids	14
Raw carrot liking	14
Salami liking	14
Schizophrenia vs ADHD (ordinary least squares (OLS))	14
Systolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test)	14
Total cholines levels	14
Total Lysophosphatidylethanolamine levels	14
Triglyceride levels x short total sleep time interaction (2df test)	14
Triglycerides to total lipids ratio in medium HDL	14
Triglycerides to total lipids ratio in small HDL	14
Tyrosine levels	14
Venous thromboembolism	14
Verbal learning (visual presentation)	14
Apolipoprotein E (isoform E4) levels	13
Apolipoprotein E levels	13
Body fat percentage or coronary artery disease (MTAG)	13
C-reactive protein levels or triglyceride levels (pleiotropy)	13
Cholesterol to total lipids ratio in large LDL	13
Cholesteryl ester levels in HDL	13
Cholesteryl ester levels in very large HDL	13
Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy)	13
Cognitive decline (age-related)	13
Diacylglycerol_44:7_[M+H-H2O]1+ levels	13
F-strong vegetable liking (derived food-liking factor)	13
Fasting linoleic acid (18:2)	13
Free cholesterol to total lipids ratio in small VLDL	13
Intake of total sugars	13
Leisure sedentary behaviour (computer use)	13
Lymphocyte-to-monocyte ratio	13
Mean arterial pressure x alcohol consumption (light vs heavy) interaction (2df test)	13
Morning vs. evening chronotype	13
Parental longevity (father's age at death)	13
Phospholipids to total lipids ratio in small VLDL	13
Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid)	13
Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid)	13
Porridge liking	13
Postprandial linoleic acid (18:2)	13
Ratio of polyunsaturated fatty acids to total fatty acids	13
Sarcoidosis (Lofgren's syndrome vs non-Lofgren's syndrome)	13
Strenuous sports or other exercises	13
Total concentration of lipoprotein particles	13
Total phospholipid levels in lipoprotein particles	13
Vigorous physical activity	13
Alzheimer disease and age of onset	12
Amyloid beta positivity in normal cognition	12
Basophil count	12
Beef consumption	12
Body mass index (age <50)	12
Cerebrospinal fluid p-tau levels	12
Cholesterol levels in very large HDL	12
Cholesterol to total lipids ratio in IDL	12
Cholesterol to total lipids ratio in medium LDL	12
Cholesterol to total lipids ratio in medium VLDL	12
Cholesteryl esters to total lipids ratio in IDL	12
Cholesteryl esters to total lipids ratio in medium VLDL	12
Cholesteryl esters to total lipids ratio in small LDL	12
Cholesteryl esters to total lipids ratio in small VLDL	12
Coffee max liking	12
Concentration of very large HDL particles	12
Cortical volume	12
COVID-19 (critical illness vs population or mild symptoms)	12
COVID-19 (hospitalized vs population)	12
Croissant liking	12
F-coffee/alcohol liking (derived food-liking factor)	12
Familial combined hyperlipidemia defined by Consensus criteria	12
Free cholesterol levels in HDL	12
Free cholesterol levels in large LDL	12
Free cholesterol levels in very large HDL	12
Free cholesterol to total lipids ratio in very small VLDL	12
Glucose levels	12
Granulocyte count	12
Hair color	12
Hepatocyte growth factor-like protein levels	12
Hippocampus volume change rate x age interaction (2df)	12
Horseradish liking	12
Idiopathic pulmonary fibrosis	12
Lipid traits	12
Lung adenocarcinoma	12
Lysophosphatidylcholine (20:1) [sn1] levels	12
Medication use (anilides)	12
Myeloid white cell count	12
Neuroticism (MTAG)	12
Ovarian cancer	12
Phosphatidate(45:6)_[M-H]1- levels	12
Phosphatidylcholine-O_32:1_[M+H]1+/Phosphatidylcholine-P_32:0_[M+H]1+/Phosphatidylethanolamine-O_35:1_[M+H]1+ levels	12
Phosphatidylcholine-O_34:1_[M+H]1+/Phosphatidylcholine-P_34:0_[M+H]1+/Phosphatidylethanolamine-O_37:1_[M+H]1+ levels	12
Phosphatidylcholine-O(36:4)_[M+H]1+/Phosphatidylcholine-P(36:3)_[M+H]1+ levels	12
Phosphatidylcholine(36:4)_[M+H]1+/Phosphatidylethanolamine(39:4)_[M+H]1+/Phosphatidate(41:5)_[M+NH4]1+ levels	12
Phosphatidylcholine(40:8)_[M+H]1+ levels	12
Phosphatidylinositol(36:3)_[M-H]1- levels	12
Phospholipid levels in HDL	12
Phospholipid levels in very large HDL	12
Phospholipids to total lipids ratio in very small VLDL	12
Platelet-to-lymphocyte ratio	12
Polyunsaturated fatty acid levels	12
Ratio of omega-3 fatty acids to total fatty acids	12
Relative protein intake	12
Schizophrenia vs anorexia nervosa (ordinary least squares (OLS))	12
Self-reported risk-taking behaviour	12
Sleep duration (long sleep)	12
Sphingomyelin_34:0_[M+H]1+ levels	12
Sphingomyelin_34:1_[M+H]1+ levels	12
Suffering from nerves	12
Sum neutrophil eosinophil counts	12
Sweet beverage consumption	12
Tea intake (UKB data field 1488)	12
Total lipid levels in lipoprotein particles	12
Total lipid levels in small LDL	12
Total lipid levels in very large HDL	12
Triglycerides to total lipids ratio in large HDL	12
Triglycerides to total lipids ratio in large LDL	12
Triglycerides to total lipids ratio in medium LDL	12
Triglycerides to total lipids ratio in medium VLDL	12
Triglycerides to total lipids ratio in small VLDL	12
Alzheimer's disease (late onset)	11
Asthma (childhood onset)	11
Balding type 1	11
Beef/steak liking	11
Body fat percentage or heart failure (MTAG)	11
C-reactive protein levels or LDL-cholesterol levels (pleiotropy)	11
Caffeine consumption	11
Cannabis smoking or cigarette smoking or schizophrenia	11
Cerebral amyloid angiopathy	11
Cholesterol levels in chylomicrons and extremely large VLDL	11
Cholesteryl ester levels in very large VLDL	11
Concentration of IDL particles	11
F-capsicum liking (derived food-liking factor)	11
F-healthy breakfast food liking (derived food-liking factor)	11
F-meat liking (derived food-liking factor)	11
Fasting apolipoprotein B	11
Fasting cholesterol esters in very small VLDL	11
Fasting polyunsaturated fatty acids	11
Fasting remnant cholesterol	11
Fasting total lipids in very small VLDL	11
Fibrinogen levels or factor VII levels (pleiotropy)	11
Free cholesterol levels in chylomicrons and extremely large VLDL	11
HDL cholesterol levels x short total sleep time interaction (2df test)	11
Hypertriglyceridemia	11
Lager liking	11
Omega-3 fatty acid levels	11
Parental longevity (father's attained age)	11
Phospholipids to total lipids ratio in medium LDL	11
Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid)	11
Postprandial apolipoprotein B	11
Postprandial omega-6 fatty acids	11
Postprandial polyunsaturated fatty acids	11
Postprandial remnant cholesterol	11
Postprandial total lipids in very small VLDL	11
Smoking status (current vs never)	11
Subcortical brain region volumes	11
Sunburns	11
Thioredoxin domain-containing protein 12 levels	11
Thyroid stimulating hormone levels	11
Total cerebellar volume (excluding Crus I vermis)	11
Total esterified cholesterol levels	11
Total free cholesterol levels	11
Total omega-3 fatty acid levels	11
Triglyceride levels in HDL	11
Triglyceride levels in IDL	11
Triglyceride levels in medium HDL	11
Triglyceride levels in small HDL	11
Triglyceride levels in very large HDL	11
Triglyceride levels x long total sleep time interaction (2df test)	11
Triglycerides to total lipids ratio in IDL	11
Triglycerides to total lipids ratio in small LDL	11
Triglycerides to total lipids ratio in very large HDL	11
Urinary metabolites (H-NMR features)	11
Urinary tract infection frequency	11
Venous thromboembolism or fibrinogen levels (pleiotropy)	11
Verbal short term memory	11
Youthful appearance (self-reported)	11
Alanine levels	10
Angina pectoris	10
aparc-Desikan rh area TotalSurface	10
aparc-DKTatlas lh area fusiform	10
aseg global volume BrainSegNotVent	10
aseg global volume BrainSegNotVentSurf	10
aseg global volume SupraTentorialNotVent	10
Asthma (adult onset)	10
Bread consumption (slices per week) (UKB data field 1438)	10
Butternut squash liking	10
Cannabis use	10
Cholesterol levels in IDL	10
Cholesterol levels in medium LDL	10
Cholesteryl ester levels in IDL	10
Cholesteryl ester levels in LDL	10
Cholesteryl ester levels in very small VLDL	10
Cholesteryl esters to total lipids ratio in large VLDL	10
Concentration of chylomicrons and extremely large VLDL particles	10
Concentration of LDL particles	10
Concentration of small LDL particles	10
Coronary artery disease or tissue plasminogen activator levels (pleiotropy)	10
Cortical surface area (global PC1)	10
Corticobasal degeneration	10
Cryptic phenotype that captures alpha-1-antitrypsin deficiency severity	10
Dementia and core Alzheimer's disease neuropathologic changes	10
Executive function (trail making test B)	10
F-caffeinated/sweet liking (derived food-liking factor)	10
F-cooking vegetables liking (derived food-liking factor)	10
F-fatty/dairy food liking (derived food-liking factor)	10
F-sauces liking (derived food-liking factor)	10
F-vegetarian liking (derived food-liking factor)	10
Fasting glucose adjusted for BMI	10
Fasting omega-3 fatty acids	10
Fibrinogen levels or factor VII levels or factor XI levels or tissue plasminogen activator levels (pleiotropy)	10
Free cholesterol levels in IDL	10
Free cholesterol levels in small HDL	10
Free cholesterol levels in small VLDL	10
Free cholesterol to total lipids ratio in medium VLDL	10
Free cholesterol to total lipids ratio in very large HDL	10
Generalized epilepsy	10
Glaucoma (primary open-angle)	10
Heart failure	10
IDP dMRI TBSS L3 Genu of corpus callosum	10
IDP dMRI TBSS MD Anterior limb of internal capsule R	10
Intracranial volume	10
Ischemic stroke	10
JT interval	10
LDL cholesterol levels x short total sleep time interaction (2df test)	10
Low hand grip strength (60 years and older) (EWGSOP)	10
Metabolic traits	10
Milky sweets liking	10
Moderate-to-vigorous intensity physical activity during leisure time	10
Neutrophil-to-lymphocyte ratio	10
Nicotine dependence	10
Omega-6 fatty acid levels	10
PCSK9 levels	10
Peak expiratory flow	10
Phosphatidylcholine-ether levels	10
Phosphatidylcholine-O_31:0_[M+H]1+/Phosphatidylethanolamine-O_34:0_[M+H]1+ levels	10
Phosphatidylinositol-O_36:1_[M+H]1+ levels	10
Phospholipid levels in chylomicrons and extremely large VLDL	10
Phospholipid levels in small LDL	10
Phospholipid levels in very small VLDL	10
Phospholipid levels in VLDL	10
Phospholipids to total lipids ratio in large HDL	10
Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid)	10
Post-traumatic stress disorder (phenotype risk score)	10
PR interval	10
Ratio of saturated fatty acids to total fatty acids	10
Red meat liking	10
Sedentary behavior at work	10
Serum phosphate levels	10
Spicy food liking	10
Subjective well-being (MTAG)	10
Sum basophil neutrophil counts	10
Systolic blood pressure x depressive symptoms interaction (2df test)	10
ThalamNuclei lh volume VAmc	10
Total lipid levels in chylomicrons and extremely large VLDL	10
Total lipid levels in IDL	10
Total lipid levels in LDL	10
Triglyceride levels in chylomicrons and extremely large VLDL	10
Uric acid levels	10
Vascular endothelial growth factor levels	10
Abdominal aortic aneurysm	9
Abdominal subcutaneous adipose tissue volume	9
Adiposity	9
Age at adiposity rebound	9
Age at menopause	9
Alzheimer's disease (age of onset) in APOE e4 non-carriers	9
Alzheimer's disease (onset between ages 58 and 79)	9
aparc-Desikan lh area fusiform	9
aparc-Desikan lh area TotalSurface	9
aseg global volume BrainSeg	9
Attention deficit hyperactivity disorder (MTAG)	9
Average diameter for VLDL particles	9
Barrett's esophagus	9
Basal metabolic rate	9
Basal metabolic rate variance	9
Bipolar disorder or body mass index	9
Blood metabolite ratios	9
Body mass index (age interaction)	9
Body mass index and bone mineral density (pleiotropy)	9
Body mass index x age interaction	9
Bone mineral density or leg lean mass (pleiotropy)	9
Brussel sprout liking	9
Cardiovascular disease risk factors	9
Celiac disease	9
Cholesterol levels in large LDL	9
Cholesterol levels in medium VLDL	9
Cholesterol levels in small LDL	9
Cholesterol to total lipids ratio in small VLDL	9
Cholesterol to total lipids ratio in very large VLDL	9
Cholesteryl ester levels	9
Cholesteryl ester levels in large LDL	9
Cholesteryl ester levels in small VLDL	9
Cholesteryl esters to total lipids ratio in large LDL	9
Cholesteryl esters to total lipids ratio in very large VLDL	9
Clinical LDL cholesterol levels	9
Coffee difference liking	9
Cognitive decline	9
Concentration of large LDL particles	9
Concentration of small VLDL particles	9
Concentration of very small VLDL particles	9
Coronary artery disease or plasminogen activator inhibitor 1 levels (pleiotropy)	9
F-cake/biscuits liking (derived food-liking factor)	9
F-glutamate liking (derived food-liking factor)	9
F-salty food liking (derived food-liking factor)	9
F-sodas liking (derived food-liking factor)	9
Factor VII activity	9
Feeling lonely	9
Free cholesterol levels in LDL	9
Free cholesterol levels in medium LDL	9
Free cholesterol levels in very small VLDL	9
Free cholesterol to total lipids ratio in small LDL	9
Free cholesterol to total lipids ratio in very large VLDL	9
Glomerular filtration rate	9
Glycoprotein acetyls levels	9
HDL cholesterol levels x long total sleep time interaction (2df test)	9
Headache	9
Hearing loss	9
Hyperopia	9
Hypertrophic cardiomyopathy	9
IDP dMRI TBSS ICVF Superior fronto-occipital fasciculus R	9
IDP dMRI TBSS L1 Superior longitudinal fasciculus R	9
IDP dMRI TBSS L3 Anterior limb of internal capsule R	9
IDP T1 SIENAX brain-normalised volume	9
IDP T1 SIENAX brain-unnormalised volume	9
IDP T1 SIENAX white normalised volume	9
IDP T1 SIENAX white unnormalised volume	9
Interstitial lung disease	9
Intracranial aneurysm	9
Ischemic stroke or fibrinogen levels (pleiotropy)	9
LDL cholesterol levels x long total sleep time interaction (2df test)	9
Leg lean mass	9
Medication use (adrenergics, inhalants)	9
Mosquito bite size	9
Peripheral artery disease	9
Phospholipid levels in IDL	9
Phospholipid levels in large LDL	9
Phospholipid levels in LDL	9
Phospholipid levels in medium LDL	9
Platelet aggregation	9
Preeclampsia (maternal genotype effect)	9
Primary sclerosing cholangitis	9
Psoriasis or type 2 diabetes (trans-disease meta-analysis)	9
Regular attendance at a pub or social club	9
Schizophrenia vs autism spectrum disorder (ordinary least squares (OLS))	9
Sphingomyelin_38:1_[M+H]1+ levels	9
Substance use disorders (time to event)	9
Tea with sugar liking	9
Total cholesterol minus HDL-C levels	9
Total lipid levels in large LDL	9
Total lipid levels in medium LDL	9
Total lipid levels in small VLDL	9
Total lipid levels in very large VLDL	9
Total lipid levels in very small VLDL	9
Total omega-6 fatty acid levels	9
Triglyceride levels in very large VLDL	9
Triglyceride levels in VLDL	9
Triglycerides to total lipids ratio in very large VLDL	9
Urate levels in overweight individuals	9
Vitiligo	9
6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)	8
Adult onset asthma or type 2 diabetes	8
Age-related hearing impairment (MTAG)	8
Aging traits (healthspan, parental lifespan or longevity) (multivariate analysis)	8
Alcohol use disorder (dependence and problematic use scores)	8
Alzheimer's disease in APOE e4- carriers	8
Apple juice liking	8
Asthma and major depressive disorder	8
Biomedical quantitative traits	8
Blood pressure	8
Blood protein levels in cardiovascular risk	8
Body fat percentage variance	8
Body mass in chronic obstructive pulmonary disease	8
Body mass index (SNP x SNP interaction)	8
C-reactive protein levels or total cholesterol levels (pleiotropy)	8
Caffeine metabolism (plasma 1,3-dimethylxanthine (theophylline) level)	8
Carotid intima media thickness (mean)	8
Cerebrospinal P-tau181p levels	8
Chicken liking	8
Childhood ear infection	8
Cholesterol levels in small HDL	8
Cholesterol levels in small VLDL	8
Cholesterol to total lipids ratio in large VLDL	8
Cholesterol to total lipids ratio in small HDL	8
Cholesteryl ester (20:4) levels	8
Cholesteryl ester (20:5) levels	8
Cholesteryl ester levels in medium LDL	8
Cholesteryl ester levels in medium VLDL	8
Cholesteryl esters to total lipids ratio in medium LDL	8
Concentration of medium LDL particles	8
Concentration of small HDL particles	8
Coronary artery disease or fibrinogen levels (pleiotropy)	8
Decaffeinated coffee consumption and/or lifetime cannabis use	8
Dentures	8
Diacylglycerol_32:2_[M+H-H2O]1+ levels	8
Diacylglycerol_34:3_[M+H-H2O]1+ levels	8
Diastolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test)	8
Estimated glomerular filtration rate in diabetes	8
F-dessert liking (derived food-liking factor)	8
F-healthy food liking (derived food-liking factor)	8
F-highly palatable foods liking (derived food-liking factor)	8
Fasting blood insulin	8
Fasting free cholesterol in medium VLDL	8
Fasting medium VLDL particle concentration	8
Fasting monounsaturated fatty acids (16:1, 18:1)	8
Fasting phospholipid levels in medium VLDL	8
Fasting total fatty acids	8
Fasting total lipids in medium VLDL	8
Free cholesterol levels in medium VLDL	8
Free cholesterol levels in VLDL	8
Free cholesterol to total lipids ratio in IDL	8
Free cholesterol to total lipids ratio in large VLDL	8
Fruit juice liking	8
Gondoic acid (20:1n-9) levels	8
HbA1c or polycystic ovary syndrome (pleiotropy)	8
HDL cholesterol x physical activity interaction (2df test)	8
Height adjusted BMI	8
Help-seeking from a GP	8
Hippocampal atrophy rate	8
Honey liking	8
IDP dMRI ProbtrackX L1 str r	8
IDP dMRI TBSS ICVF Anterior limb of internal capsule R	8
IDP dMRI TBSS L2 Genu of corpus callosum	8
IDP dMRI TBSS MD Anterior limb of internal capsule L	8
Kidney volume	8
Lean mass index	8
Liver fat content (MRI proton density fat fraction measure)	8
Longevity (90 years and older)	8
Low testosterone levels	8
Male puberty timing (early vs. average onset facial hair)	8
Medication use (opioids)	8
Microalbuminuria	8
Number of decayed, missing and filled tooth surfaces or use of dentures	8
Obstructive sleep apnea	8
Oleic acid (18:1n-9) levels	8
Orange juice liking	8
Palmitoleic acid (16:1n-7) levels	8
Parental longevity (both parents in top 10%)	8
Percent liver fat	8
Phosphatidylcholine-2O_32:0_[M+H]1+ levels	8
Phosphatidylcholine-O_30:1_[M+H]1+/Phosphatidylcholine-P_30:0_[M+H]1+/Phosphatidylethanolamine-O_33:1_[M+H]1+ levels	8
Phosphatidylcholine-O_34:3_[M+H]1+/Phosphatidylcholine-P_34:2_[M+H]1+/Phosphatidylethanolamine-P_37:2_[M+H]1+ levels	8
Phosphatidylcholine-O_36:2_[M+H]1+/Phosphatidylcholine-P_36:1_[M+H]1+/Phosphatidylethanolamine-P_39:1_[M+H]1+ levels	8
Phospholipid levels in small VLDL	8
Phospholipids to total lipids ratio in chylomicrons and extremely large VLDL	8
Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid)	8
Postprandial free cholesterol in IDL	8
Postprandial free cholesterol in large LDL	8
Postprandial monounsaturated fatty acids (16:1, 18:1)	8
Postprandial phospholipid levels in IDL	8
Postprandial phospholipid levels in medium VLDL	8
Postprandial phospholipid levels in small HDL	8
Postprandial saturated fatty acids	8
Postprandial total fatty acids	8
Postprandial triglyceride levels	8
Pure non-grapefruit juice consumption	8
Ratio of omega-6 fatty acids to total fatty acids	8
Remnant cholesterol (non-HDL, non-LDL -cholesterol)	8
Roast chicken liking	8
Sasang constitutional medicine type (So-Eum)	8
Schizophrenia vs bipolar disorder (ordinary least squares (OLS))	8
Serum type 1 collagen metabolite levels	8
Sex hormone-binding globulin levels in postmenopausal women	8
Sleep apnea syndrome	8
Sugar-sweetened beverage consumption	8
Tea difference liking	8
Total lipid levels in medium VLDL	8
Trauma exposure	8
Triglycerides to total lipids ratio in large VLDL	8
Trunk fat mass	8
Type 2 diabetes (adjusted for BMI)	8
Type 2 diabetes (adjusted for BMI) or polycystic ovary syndrome (pleiotropy)	8
Type 2 diabetes nephropathy	8
Type 2 diabetes nephropathy including microalbuminuria	8
Type 2 diabetes or polycystic ovary syndrome (pleiotropy)	8
Urinary albumin excretion	8
Urinary metabolite levels in chronic kidney disease	8
Urinary potassium excretion	8
Visceral adipose tissue volume	8
Voxel-wise structural brain imaging measurements	8
Waist circumference adjusted for BMI (adjusted for smoking behaviour)	8
Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction)	8
Waist-to-hip ratio adjusted for body mass index	8
White bread liking	8
1-oleoyl-2-linoleoyl-GPE (18:1/18:2) levels in elite athletes	7
Alcohol consumption in current drinkers	7
Alzheimer's disease (onset at age over 80)	7
Alzheimer's disease progression score	7
Ascending aorta maximum area	7
aseg rh intensity Putamen	7
Baked/steamed fish liking	7
Beans liking	7
Body mass index and systole blood pressure (pairwise)	7
Carotid intima media thickness (maximum)	7
Childhood maltreatment	7
Cholesterol levels in very small VLDL	7
Cholesteryl ester levels in small HDL	7
Cholesteryl ester levels in VLDL	7
Concentration of VLDL particles	7
Corneal resistance factor (MTAG)	7
Coronary artery calcification	7
Coronary artery disease (myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease)	7
Coronary artery disease or factor VII levels (pleiotropy)	7
Coronary artery disease or von Willebrand factor levels (pleiotropy)	7
Cortical surface area (min-P)	7
Cortical thickness (min-P)	7
COVID-19 (critical illness vs population)	7
Deliberate self-harm	7
Diacylglycerol_34:2_[M+H-H2O]1+ levels	7
Diacylglycerol_36:4_[M+H-H2O]1+ levels	7
F-bitter food liking (derived food-liking factor)	7
F-dairy liking (derived food-liking factor)	7
F-oily fish liking (derived food-liking factor)	7
Familial combined hyperlipidemia defined by Dutch criteria	7
Fasting serum total triglycerides	7
Fasting triglyceride levels	7
Fasting triglycerides in VLDL	7
Fasting triglycerides levels in medium VLDL	7
Fasting triglycerides levels in small HDL	7
Fasting triglycerides levels in small VLDL	7
Fibrinogen levels or plasminogen activator inhibitor 1 levels (pleiotropy)	7
Fibrinogen levels or tissue plasminogen activator levels (pleiotropy)	7
Free cholesterol to total lipids ratio in small HDL	7
Generalized anxiety disorder (mental health questionnaire or predicted)	7
Generalized anxiety disorder (phenotype risk score)	7
Glutamine levels	7
Graves' disease	7
Gut microbiota abundance (genus Bifidobacterium id.436)	7
Hay fever and/or eczema	7
IDP dMRI ProbtrackX MD atr l	7
IDP dMRI TBSS ICVF Anterior corona radiata R	7
IDP dMRI TBSS ICVF Retrolenticular part of internal capsule L	7
IDP dMRI TBSS L2 Superior fronto-occipital fasciculus L	7
IDP dMRI TBSS OD Cerebral peduncle R	7
IDP SWI T2star left caudate	7
IDP SWI T2star left putamen	7
IDP SWI T2star right caudate	7
Irritable bowel syndrome	7
Joint mobility (Beighton score)	7
Knee osteoarthritis	7
Late-onset Alzheimer's disease	7
Linoleoyl-arachidonoyl-glycerol (18:2/20:4) [2] levels	7
Male puberty timing (late vs. average onset facial hair)	7
Male puberty timing (late vs. average onset voice breaking)	7
Medication use (salicylic acid and derivatives)	7
Parental longevity (mother's attained age)	7
Pediatric autoimmune diseases	7
Percentage of invited food questionnaires completed	7
Phospholipid levels in small HDL	7
Phospholipids to total lipids ratio in IDL	7
Phospholipids to total lipids ratio in very large VLDL	7
Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid)	7
Pneumonia	7
Postprandial free cholesterol in medium VLDL	7
Postprandial medium VLDL particle concentration	7
Postprandial serum total triglycerides	7
Postprandial total lipids in medium VLDL	7
Postprandial triglycerides in VLDL	7
Postprandial triglycerides levels in medium VLDL	7
Postprandial triglycerides levels in small VLDL	7
Principal component-derived dietary pattern 3	7
Raw vegetable consumption	7
SARS-CoV-2 infection	7
Serum levels of protein APOB	7
Serum levels of protein C5orf38	7
Serum levels of protein CKAP2	7
Serum levels of protein CTF1	7
Serum levels of protein PSME1	7
Smoking behaviour (cigarette pack-years)	7
Stromelysin-1 levels	7
Total lipid levels in small HDL	7
Triglyceride levels in large HDL	7
Triglycerides x physical activity interaction (2df test)	7
Uterine leiomyoma or breast cancer (pleiotropy)	7
Very low density lipoprotein cholesterol levels	7
VLDL cholesterol levels	7
Waist circumference adjusted for BMI in non-smokers	7
Water consumption (glasses per day) (UKB data field 1528)	7
White matter hyperintensities	7
White matter mean diffusivity x age interaction (2df)	7
3-Hydroxybutyrate levels	6
3-hydroxyoctanoate levels in elite athletes	6
Accelerometer-based physical activity measurement (average acceleration)	6
Advanced age-related macular degeneration	6
Age of onset of parkinson disease	6
Age-related cognitive decline (memory) (slope of z-scores)	6
Allergic rhinitis	6
Alzheimer's disease assessment scale (12 month visit)	6
Alzheimer's disease assessment scale (24 month visit)	6
Alzheimer's disease assessment scale (6 month visit)	6
Alzheimer's disease assessment scale (baseline)	6
Alzheimer's disease in hypertension	6
Alzheimer's disease in hypertension-negative individuals	6
Alzheimer’s disease (clinical subgroup AD+)	6
Alzheimer’s disease (clinical subgroup AD++)	6
Alzheimer’s disease (clinical subgroup AD+++)	6
Alzheimer’s disease and/or vascular dementia (clinical subgroup VaD+)	6
Amygdala volume change rate x age interaction (1df)	6
Amygdala volume change rate x age interaction (2df)	6
AmygNuclei lh volume Medial-nucleus	6
AmygNuclei rh volume Cortical-nucleus	6
AmygNuclei rh volume Medial-nucleus	6
Amyloid (PET imaging) (24 month visit)	6
Amyloid (PET imaging) (baseline)	6
Amyloid pathology	6
Amyloid status (abnormal vs normal)	6
Apo E plasma levels	6
aseg lh intensity Accumbens-area	6
aseg lh intensity Pallidum	6
aseg lh intensity Putamen	6
aseg rh intensity Accumbens-area	6
aseg rh intensity Pallidum	6
aseg rh volume Pallidum	6
Aspartate aminotransferase platelet ratio index in high alcohol intake	6
Attention deficit hyperactivity disorder	6
Autism spectrum disorder (MTAG)	6
Autoimmune thyroid disease	6
Barrett's esophagus  or Esophageal adenocarcinoma	6
BBQ/grilled meat liking	6
Body mass index and LDL-C (pairwise)	6
Brain rsFMRI measurement (amplitude of low frequency fluctations) (Net100_Node39)	6
Brain rsFMRI measurement (amplitude of low frequency fluctations) (Net100_Node42)	6
Brain rsFMRI measurement (amplitude of low frequency fluctations) (Net25_Node5)	6
Breast cancer (male)	6
Broad bean liking	6
Burger liking	6
Cabbage liking	6
Carotid intima media thickness	6
Central cerebrospinal fluid amyloid beta 42 levels	6
Central cerebrospinal fluid amyloid beta 42 to 40 ratio	6
Central cerebrospinal fluid amyloid beta 42 to 40 ratio (abnormal vs normal)	6
Ceramide (d18:2/20:0) levels	6
Cerebral amyloid angiopathy in APOEe4 carrier Alzheimer’s disease	6
Cerebral amyloid deposition positivity (PET imaging)	6
Cerebral cortex AV-45 amyloid PET measurement	6
Cerebral microbleeds	6
Cerebral microbleeds (lobar)	6
Cerebrospinal AB1-42 levels in Alzheimer's disease dementia	6
Cerebrospinal AB1-42 levels in mild cognitive impairment	6
Cerebrospinal AB1-42 levels in normal cognition	6
Cerebrospinal fluid amyloid beta 42 levels	6
Cerebrospinal fluid amyloid beta 42 levels (12 month visit)	6
Cerebrospinal fluid amyloid beta 42 levels (24 month visit)	6
Cerebrospinal fluid amyloid beta 42 levels (baseline)	6
Cerebrospinal fluid amyloid beta 42 levels in APOE e4 carriers	6
Cerebrospinal fluid amyloid beta 42 levels in normal amyloid levels	6
Cerebrospinal fluid biomarker levels	6
Cerebrospinal fluid p-tau levels (12 month visit)	6
Cerebrospinal fluid p-tau levels (24 month visit)	6
Cerebrospinal fluid p-tau levels (baseline)	6
Cerebrospinal fluid p-tau levels in mild cognitive impairment	6
Cerebrospinal fluid p-tau levels in normal amyloid levels	6
Cerebrospinal fluid t-tau levels (24 month visit)	6
Cerebrospinal fluid t-tau levels (baseline)	6
Cerebrospinal fluid t-tau levels in mild cognitive impairment	6
Cerebrospinal T-tau levels	6
Change in serum metabolite levels	6
Change in serum metabolite levels (CMS)	6
Cheese consumption	6
Cholesteryl ester (24:1) levels	6
Cholesteryl ester levels in small LDL	6
Concentration of medium VLDL particles	6
Cortical amyloid beta load	6
Cream liking	6
Decaffeinated coffee consumption and/or insomnia	6
DHEAS levels	6
Diastolic blood pressure (cigarette smoking interaction)	6
Diastolic blood pressure x low social support interaction (2df test)	6
Diffuse plaques	6
Diverticular disease	6
Endometriosis or migraine	6
Endothelial monocyte-activating polypeptide 2 levels	6
Entorhinal cortical thickness	6
Entorhinal cortical volume (12 month visit)	6
Entorhinal cortical volume (24 month visit)	6
Entorhinal cortical volume (6 month visit)	6
Entorhinal cortical volume (baseline)	6
Epilepsy	6
F-carbohydrate liking (derived food-liking factor)	6
F-salad vegetables liking (derived food-liking factor)	6
Familial combined hyperlipidemia defined by Mexico criteria	6
Fasting 3-hydroxybutyrate	6
Fasting cholesterol esters in IDL	6
Fasting cholesterol esters in large LDL	6
Fasting cholesterol esters in medium HDL	6
Fasting cholesterol esters in medium LDL	6
Fasting cholesterol esters in medium VLDL	6
Fasting cholesterol esters in small LDL	6
Fasting cholesterol esters in small VLDL	6
Fasting esterified cholesterol	6
Fasting free cholesterol	6
Fasting free cholesterol in IDL	6
Fasting free cholesterol in large LDL	6
Fasting free cholesterol in medium LDL	6
Fasting free cholesterol in small LDL	6
Fasting free cholesterol in small VLDL	6
Fasting free cholesterol in very small VLDL	6
Fasting IDL particle concentration	6
Fasting large LDL particle concentration	6
Fasting medium LDL particle concentration	6
Fasting omega-6 fatty acids	6
Fasting phospholipid levels in IDL	6
Fasting phospholipid levels in large LDL	6
Fasting phospholipid levels in medium LDL	6
Fasting phospholipid levels in small HDL	6
Fasting phospholipid levels in small LDL	6
Fasting phospholipid levels in small VLDL	6
Fasting phospholipid levels in very small VLDL	6
Fasting saturated fatty acids	6
Fasting serum total cholesterol	6
Fasting small LDL particle concentration	6
Fasting small VLDL particle concentration	6
Fasting total cholesterol in IDL	6
Fasting total cholesterol in large LDL	6
Fasting total cholesterol in LDL	6
Fasting total cholesterol in medium LDL	6
Fasting total cholesterol in medium VLDL	6
Fasting total cholesterol in small LDL	6
Fasting total cholesterol in small VLDL	6
Fasting total cholesterol in very small VLDL	6
Fasting total cholesterol in VLDL	6
Fasting total lipids in IDL	6
Fasting total lipids in large LDL	6
Fasting total lipids in medium LDL	6
Fasting total lipids in small LDL	6
Fasting total lipids in small VLDL	6
Fasting triglycerides in LDL	6
Fasting triglycerides levels in IDL	6
Fasting triglycerides levels in large LDL	6
Fasting triglycerides levels in medium LDL	6
Fasting triglycerides levels in small LDL	6
Fasting triglycerides levels in very large HDL	6
Fasting very small VLDL particle concentration	6
Fluorodeoxyglucose (PET imaging) (24 month visit)	6
Fluorodeoxyglucose (PET imaging) (baseline)	6
Frailty index	6
Free cholesterol levels in small LDL	6
Functional activities questionnaire (12 month visit)	6
Functional activities questionnaire (24 month visit)	6
Functional activities questionnaire (6 month visit)	6
Functional activities questionnaire (baseline)	6
Fusiform volume (12 month visit)	6
Fusiform volume (24 month visit)	6
Fusiform volume (6 month visit)	6
Fusiform volume (baseline)	6
Global cognition (Clinical Dementia Rating Scale Sum of Boxes) (12 month visit)	6
Global cognition (Clinical Dementia Rating Scale Sum of Boxes) (24 month visit)	6
Global cognition (Clinical Dementia Rating Scale Sum of Boxes) (6 month visit)	6
Global cognition (Clinical Dementia Rating Scale Sum of Boxes) (baseline)	6
Glomerular filtration rate (creatinine)	6
Goat cheese liking	6
Gut microbiota abundance (phylum Actinobacteria id.400)	6
Haemorrhoidal disease	6
Hard cheese liking	6
High-sensitivity C-reactive protein levels in HIV infection	6
High-sensitivity cardiac troponin T levels	6
Hip fracture	6
Hippocampal volume (12 month visit)	6
Hippocampal volume (24 month visit)	6
Hippocampal volume (6 month visit)	6
Hippocampal volume (baseline)	6
IDP dMRI ProbtrackX OD str l	6
IDP dMRI TBSS FA Fornix	6
IDP dMRI TBSS ICVF Cerebral peduncle L	6
IDP dMRI TBSS ICVF Cerebral peduncle R	6
IDP dMRI TBSS ISOVF Fornix	6
IDP dMRI TBSS L2 Fornix	6
IDP dMRI TBSS L3 Fornix	6
IDP dMRI TBSS MD Cingulum cingulate gyrus R	6
IDP dMRI TBSS MD Fornix	6
IDP dMRI TBSS MO Cerebral peduncle L	6
IDP dMRI TBSS MO Cerebral peduncle R	6
IDP dMRI TBSS OD Anterior limb of internal capsule L	6
IDP dMRI TBSS OD Cerebral peduncle L	6
IDP SWI T2star left pallidum	6
IDP SWI T2star right pallidum	6
IDP T1 FAST ROIs L cerebellum I-IV	6
IDP T1 FAST ROIs L cerebellum IX	6
IDP T1 FAST ROIs L cerebellum VIIIb	6
IDP T1 FAST ROIs L putamen	6
IDP T1 FAST ROIs L ventral striatum	6
IDP T1 FAST ROIs R cerebellum IX	6
IDP T1 FAST ROIs R putamen	6
IDP T1 FAST ROIs V cerebellum IX	6
IDP T1 FAST ROIs V cerebellum VIIIa	6
IDP T1 FAST ROIs V cerebellum VIIIb	6
Inferior parietal cortical thickness	6
Information processing speed (symbol digit substitution)	6
Lamb liking	6
Lateral ventricle volume change rate x age interaction (2df)	6
Lateral ventricular volume in normal aging	6
LDL cholesterol to HDL cholesterol ratio	6
Logical memory (delayed recall)	6
Logical memory (immediate recall)	6
Loneliness (MTAG)	6
Longevity (100 years and older)	6
Longevity (85 years and older)	6
Low high density lipoprotein cholesterol levels	6
Lung function in never smokers (low FEV1 vs high FEV1)	6
Lysophosphatidylcholine (20:0) [sn2] levels	6
Lysophosphatidylcholine 20:4 levels	6
lysoPhosphatidylcholine acyl C26:1 levels	6
Lysophosphatidylethanolamine_16:0_[M-H]1- levels	6
Meningioma	6
Middle temporal cortical thickness	6
Middle temporal gyrus volume (12 month visit)	6
Middle temporal gyrus volume (6 month visit)	6
Middle temporal gyrus volume (baseline)	6
Mini-mental state examination / Folstein test (12 month visit)	6
Mini-mental state examination / Folstein test (24 month visit)	6
Mini-mental state examination / Folstein test (6 month visit)	6
Mini-mental state examination / Folstein test (baseline)	6
Moderate-to-vigorous intensity physical activity during leisure time (MTAG)	6
Monohexosylceramide (d18:1/22:0) levels	6
Monohexosylceramide (d18:1/24:0) levels	6
Mortality	6
Neuritic plaques or cerebral amyloid angiopathy (pleiotropy)	6
Neuritic plaques or neurofibrillary tangles (pleiotropy)	6
Neurofibrillary tangles or cerebral amyloid angiopathy (pleiotropy)	6
Neuropathologic traits (pleiotropy)	6
Neutrophil collagenase levels	6
Non-melanoma skin cancer	6
Offspring birth weight	6
Osteoarthritis (hip)	6
Parkinson's disease (age of onset)	6
Parkinson's disease progression (cognitive)	6
Parkinson's disease progression (composite)	6
Phosphatidylcholine diacyl C34:4 levels	6
Phosphatidylcholine diacyl C38:5 levels	6
Phosphatidylcholine-O_34:2_[M+H]1+/Phosphatidylcholine-P_34:1_[M+H]1+/Phosphatidylethanolamine-O_37:2_[M+H]1+ levels	6
Phosphatidylcholine-O_36:3_[M+H]1+/Phosphatidylcholine-P_36:2_[M+H]1+ levels	6
Phosphatidylinositol levels	6
Phospholipid levels in medium VLDL	6
Photic sneeze reflex	6
Physical activity (Total log acceleration 8am-10am)	6
Physical activity (Total log acceleration)	6
Plasma amyloid beta peptide concentration (ABx-40/ABx-42 ratio)	6
Plasma amyloid beta peptide concentrations (ABx-42)	6
Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid)	6
Plasma p-tau181 levels	6
Postprandial 3-hydroxybutyrate	6
Postprandial cholesterol esters in chylomicrons and extremely large VLDL	6
Postprandial cholesterol esters in IDL	6
Postprandial cholesterol esters in large LDL	6
Postprandial cholesterol esters in medium HDL	6
Postprandial cholesterol esters in medium LDL	6
Postprandial cholesterol esters in medium VLDL	6
Postprandial cholesterol esters in small LDL	6
Postprandial cholesterol esters in small VLDL	6
Postprandial cholesterol esters in very small VLDL	6
Postprandial esterified cholesterol	6
Postprandial free cholesterol	6
Postprandial free cholesterol in medium HDL	6
Postprandial free cholesterol in medium LDL	6
Postprandial free cholesterol in small HDL	6
Postprandial free cholesterol in small LDL	6
Postprandial free cholesterol in small VLDL	6
Postprandial free cholesterol in very small VLDL	6
Postprandial IDL particle concentration	6
Postprandial large LDL particle concentration	6
Postprandial medium HDL particle concentration	6
Postprandial medium LDL particle concentration	6
Postprandial phospholipid levels in large LDL	6
Postprandial phospholipid levels in medium HDL	6
Postprandial phospholipid levels in medium LDL	6
Postprandial phospholipid levels in small LDL	6
Postprandial phospholipid levels in small VLDL	6
Postprandial phospholipid levels in very small VLDL	6
Postprandial serum total cholesterol	6
Postprandial small HDL particle concentration	6
Postprandial small LDL particle concentration	6
Postprandial small VLDL particle concentration	6
Postprandial total cholesterol in IDL	6
Postprandial total cholesterol in large LDL	6
Postprandial total cholesterol in LDL	6
Postprandial total cholesterol in medium HDL	6
Postprandial total cholesterol in medium LDL	6
Postprandial total cholesterol in medium VLDL	6
Postprandial total cholesterol in small LDL	6
Postprandial total cholesterol in small VLDL	6
Postprandial total cholesterol in very small VLDL	6
Postprandial total cholesterol in VLDL	6
Postprandial total lipids in IDL	6
Postprandial total lipids in large LDL	6
Postprandial total lipids in medium HDL	6
Postprandial total lipids in medium LDL	6
Postprandial total lipids in small HDL	6
Postprandial total lipids in small LDL	6
Postprandial total lipids in small VLDL	6
Postprandial triglycerides in LDL	6
Postprandial triglycerides levels in IDL	6
Postprandial triglycerides levels in large LDL	6
Postprandial triglycerides levels in medium LDL	6
Postprandial triglycerides levels in small LDL	6
Postprandial triglycerides levels in very large HDL	6
Postprandial very small VLDL particle concentration	6
Primary biliary cirrhosis	6
QRS duration	6
Ratio of apolipoprotein B to apolipoprotein A1 levels	6
Ratio of linoleic acid to total fatty acids	6
Respiratory diseases	6
Rey auditory verbal learning test (12 month visit)	6
Rey auditory verbal learning test (24 month visit)	6
Rey auditory verbal learning test (6 month visit)	6
Rey auditory verbal learning test (baseline)	6
Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive)	6
Savoury biscuit liking	6
Serum C-reactive protein concentration	6
Serum levels of protein AIMP1	6
Serum levels of protein BIRC2	6
Serum levels of protein CLK2	6
Serum levels of protein CPE	6
Serum levels of protein CRP	6
Serum levels of protein CRYZL1	6
Serum levels of protein CUZD1	6
Serum levels of protein IRF6	6
Serum levels of protein MSN	6
Serum levels of protein NDE1	6
Serum levels of protein PLA2G7	6
Serum levels of protein POLR1C	6
Serum levels of protein PSD	6
Serum levels of protein RALA	6
Serum levels of protein SNRPF	6
Serum levels of protein YWHAE	6
Small nuclear ribonucleoprotein F levels	6
Smoking behavior	6
Sphingomyelin_33:1_[M+H]1+ levels	6
Sphingomyelin(37:1)_[M+H]1+ levels	6
Stable angina pectoris	6
Stool frequency	6
Stroke	6
Sulfatide (d18:1/24:0(OH) levels) levels	6
Sum eosinophil basophil counts	6
Superior frontal cortical thickness	6
Systolic blood pressure (cigarette smoking interaction)	6
Total brain volume change rate x age interaction (2df)	6
Tourette syndrome	6
Triacylglycerol 56:6 levels	6
Triacylglycerol_50:3_[M+NH4]1+ levels	6
Triacylglycerol_50:4_[M+NH4]1+ levels	6
Trihexosylcermide (d18:1/18:0) levels	6
Tuberculosis	6
Urinary albumin excretion (no hypertensive medication)	6
Uterine leiomyoma or ER positive breast cancer (pleiotropy)	6
Venous thromboembolism or factor VII levels (pleiotropy)	6
Verbal memory performance (residualized delayed recall level)	6
Waist-to-hip ratio adjusted for BMI in active individuals	6
1-palmitoyl-2-linoleoyl-GPE (16:0/18:2) levels in elite athletes	5
Albumin-globulin ratio	5
Alcohol consumption (drinkers vs non-drinkers)	5
Alkenylphosphatidylcholine (P-17:0/20:4) (a) levels	5
Alkenylphosphatidylcholine (P-17:0/20:4) (b) levels	5
Alkenylphosphatidylcholine (P-18:0/20:4) levels	5
Alkenylphosphatidylcholine (P-18:0/22:5) levels	5
Alkenylphosphatidylcholine (P-38:5) (b) levels	5
Alkenylphosphatidylethanolamine (P-16:0/20:3) (a) levels	5
Alkenylphosphatidylethanolamine (P-17:0/20:4) (a) levels	5
Alkenylphosphatidylethanolamine (P-17:0/20:4) (b) levels	5
Alkenylphosphatidylethanolamine (P-18:0/20:4) levels	5
Alkenylphosphatidylethanolamine (P-18:1/20:3) (a) levels	5
Alkenylphosphatidylethanolamine (P-18:1/20:3) (b) levels	5
Alkenylphosphatidylethanolamine (P-19:0/20:4) (b) levels	5
Alkylphosphatidylcholine (O-18:0/20:4) levels	5
AmygNuclei lh volume Central-nucleus	5
AmygNuclei rh volume Central-nucleus	5
Anthropometric traits	5
Anthropometric traits (multi-trait analysis)	5
aparc-a2009s lh area S-collat-transv-ant	5
aparc-a2009s lh thickness S-orbital-H-Shaped	5
aparc-a2009s rh area G-oc-temp-lat-fusifor	5
aparc-Desikan rh area lateraloccipital	5
aparc-Desikan rh volume fusiform	5
aparc-DKTatlas rh area lateraloccipital	5
aparc-pial lh area TotalSurface	5
aparc-pial rh area TotalSurface	5
Ascending aorta minimum area	5
Ascending thoracic aortic diameter	5
aseg global volume SupraTentorial	5
aseg lh volume CerebralWhiteMatter	5
aseg rh intensity Caudate	5
aseg rh volume CerebralWhiteMatter	5
Atrial fibrillation (MTAG)	5
Autism and educational attainment (MTAG)	5
BA-exvivo rh area V2	5
Bitter taste perception	5
Body mass index and triglycerides (pairwise)	5
Brain amyloid deposition (PET imaging)	5
Cannabis use disorder	5
Carotid intima media thickness (minimum)	5
Central corneal thickness (MTAG)	5
Cerebral amyloid angiopathy in Alzheimer’s disease	5
Cerebrospinal fluid amyloid beta 42 levels in abnormal amyloid levels	5
Cholesteryl ester (16:0) levels	5
Cholesteryl ester (24:6) levels	5
Cholesteryl esters to total lipids ratio in small HDL	5
Cognitive impairment	5
Coronary artery disease or factor XI levels (pleiotropy)	5
Curry liking	5
Cystatin C plasma levels	5
Diacylglycerol (18:1_20:3) levels	5
Diacylglycerol (18:1_20:4) levels	5
Driving (hours per day)	5
Dyslipidemia	5
Early-onset ischemic stroke	5
Endometriosis or depression (pleiotropy)	5
Eosinophil percentage of granulocytes	5
Estimated glomerular filtration rate in non-diabetics	5
F-sweetened coffee drink liking (derived food-liking factor)	5
F-wine liking (derived food-liking factor)	5
Familial combined hyperlipidemia defined by Brunzell criteria	5
Fasting blood glucose (BMI interaction)	5
Fasting blood glucose adjusted for BMI	5
Fasting cholesterol esters in large VLDL	5
Fasting cholesterol esters in very large VLDL	5
Fasting free cholesterol in large VLDL	5
Fasting large VLDL particle concentration	5
Fasting phospholipid levels in large VLDL	5
Fasting phospholipid levels in very large VLDL	5
Fasting total cholesterol in large VLDL	5
Fasting total lipids in large VLDL	5
Fasting total lipids in very large VLDL	5
Fasting triglycerides levels in large VLDL	5
Fasting triglycerides levels in very small VLDL	5
Forns index in high alcohol intake	5
Free cholesterol to total lipids ratio in chylomicrons and extremely large VLDL	5
Frontotemporal dementia	5
Gastroesophageal reflux disease, peptic ulcer disease and/or corresponding medications and treatment	5
Glaucoma	5
Gut microbiota abundance (family Bifidobacteriaceae id.433)	5
Gut microbiota abundance (order Bifidobacteriales id.432)	5
Handedness (Left-handed vs. non-left-handed)	5
High-sensitivity cardiac troponin I concentration (MTAG)	5
High-sensitivity cardiac troponin T levels (MTAG)	5
Hypertrophic cardiomyopathy (sarcomere negative)	5
IDP dMRI ProbtrackX L1 atr l	5
IDP dMRI ProbtrackX L1 slf r	5
IDP dMRI ProbtrackX MD str l	5
IDP dMRI TBSS ICVF Genu of corpus callosum	5
IDP dMRI TBSS L1 Anterior corona radiata L	5
IDP dMRI TBSS L1 External capsule R	5
IDP dMRI TBSS L3 Anterior limb of internal capsule L	5
IDP dMRI TBSS MD Anterior corona radiata L	5
IDP dMRI TBSS MD Anterior corona radiata R	5
IDP dMRI TBSS MD Cingulum cingulate gyrus L	5
IDP T1 FAST ROIs R cerebellum VIIIb	5
IDP T1 FAST ROIs R ventral striatum	5
Ischemic stroke or factor VII levels (pleiotropy)	5
Lactate dehydrogenase levels	5
Lactate levels	5
Lateral thalamic nuclei volume	5
Leucine levels	5
Liver enzyme levels	5
Lobar intracerebral hemorrhage	5
Lumbar spine bone mineral density	5
Lysoalkenylphosphatidylcholine (P-16:0) levels	5
Lysoalkenylphosphatidylcholine (P-18:0) levels	5
Lysoalkylphosphatidylcholine (O-16:0) levels	5
Lysoalkylphosphatidylcholine (O-18:0) levels	5
Lysophosphatidylethanolamine (20:4) [sn1] levels	5
Major depressive disorder (lifetime)	5
Marzipan liking	5
Medication use (vasodilators used in cardiac diseases)	5
MHC class I polypeptide-related sequence B levels	5
Mitochondrial DNA copy number	5
Moderate to vigorous physical activity duration	5
Neutrophil percentage of granulocytes	5
Non-small cell lung cancer	5
Nonatopic asthma	5
Oleoyl-arachidonoyl-glycerol (18:1/20:4) [1] levels	5
Osteoporosis-related phenotypes (MTAG)	5
OTU99_8 (Ruminococcaceae) prevalence	5
Phosphatidylcholine (16:0_16:0) levels	5
Phosphatidylcholine (16:1_18:2) levels	5
Phosphatidylcholine (36:0) levels	5
Phosphatidylcholine-O(39:1)_[M+H]1+/Phosphatidylethanolamine-P(39:0)_[M+H]1+ levels	5
Postprandial cholesterol esters in large VLDL	5
Postprandial cholesterol esters in very large VLDL	5
Postprandial free cholesterol in large VLDL	5
Postprandial large VLDL particle concentration	5
Postprandial phospholipid levels in large VLDL	5
Postprandial total cholesterol in large VLDL	5
Postprandial total cholesterol in very large VLDL	5
Postprandial total lipids in large VLDL	5
Postprandial triglycerides levels in large VLDL	5
Postprandial triglycerides levels in small HDL	5
Postprandial triglycerides levels in very small VLDL	5
Processed meat consumption	5
Progressive supranuclear palsy	5
Protein quantitative trait loci	5
Receptor for advanced glycosylation end products levels	5
Regular attendance at a gym or sports club	5
Remission after SSRI treatment in MDD or neuroticism	5
Renal underexcretion gout	5
Serum levels of protein ADAM11	5
Serum levels of protein AKT2	5
Serum levels of protein ARFGAP1	5
Serum levels of protein C1orf56	5
Serum levels of protein FAM159B	5
Serum levels of protein GAL3ST2	5
Serum levels of protein GGT2	5
Serum levels of protein GSTM1	5
Serum levels of protein HBQ1	5
Serum levels of protein HDAC8	5
Serum levels of protein HLA-DRB3	5
Serum levels of protein IFIT2	5
Serum levels of protein NEFL	5
Serum levels of protein NPTX2	5
Serum levels of protein PSG5	5
Serum levels of protein RAB14	5
Serum levels of protein TMCC3	5
Serum levels of protein TOM1L1	5
Serum levels of protein TP53I11	5
Serum levels of protein YWHAQ	5
Sex hormone-binding globulin levels in premenopausal women	5
Smoking status (current vs mixed)	5
Soft cheese liking	5
Spherical equivalent or myopia (age of diagnosis)	5
Sphingomyelin (d18:0/22:0) levels	5
Sphingomyelin(34:0)_[M+H]1+ levels	5
Sun-seeking behavior	5
Total Lysoalkenylphosphatidylcholine levels	5
Urate levels in obese individuals	5
Varicella zoster virus glycoproteins E and I antibody levels	5
Vegetables liking	5
Ventral diencephalon volume	5
Vitamin D levels	5
Waist Circumference - Triglycerides (WC-TG)	5
Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction)	5
wg lh intensity-contrast isthmuscingulate	5
wg rh intensity-contrast middletemporal	5
White matter hyperintensity volume x hypertension interaction (2df)	5
1-arachidonoyl-gpc (20:4n6) levels	4
1-myristoyl-2-arachidonoyl-GPC (14:0/20:4) levels	4
1-palmitoyl-2-arachidonoyl-gpc (16:0/20:4n6) levels	4
1-stearoyl-2-arachidonoyl-gpc (18:0/20:4) levels	4
1-stearoyl-2-oleoyl-GPE (18:0/18:1) levels	4
Acetate levels	4
Acne (severe)	4
AFP levels	4
Alkenylphosphatidylcholine (P-15:0/20:4) (b) levels	4
Alkenylphosphatidylcholine (P-16:0/20:4) levels	4
Alkenylphosphatidylcholine (P-20:0/20:4) levels	4
Alkenylphosphatidylcholine (P-38:5) (a) levels	4
Alkenylphosphatidylethanolamine (P-16:0/20:4) levels	4
Alkenylphosphatidylethanolamine (P-18:1/20:4) (a) levels	4
Alkenylphosphatidylethanolamine (P-18:1/20:4) (b) levels	4
Alkenylphosphatidylethanolamine (P-19:0/20:4) (a) levels	4
Alkenylphosphatidylethanolamine (P-20:0/20:4) levels	4
Alkenylphosphatidylethanolamine (P-20:1/20:4) levels	4
Alkylphosphatidylcholine (O-16:0/20:3) levels	4
Alkylphosphatidylcholine (O-16:0/20:4) levels	4
Alkylphosphatidylcholine (O-38:5) levels	4
Alkylphosphatidylcholine (O-40:5) levels	4
Alkylphosphatidylethanolamine (O-16:0/20:3) levels	4
Alkylphosphatidylethanolamine (O-18:0/20:4) levels	4
Alzheimer's disease (age of onset) (adjusted for APOE e4 carrier status)	4
AmygNuclei lh volume Accessory-Basal-nucleus	4
AmygNuclei lh volume Cortical-nucleus	4
AmygNuclei rh volume Accessory-Basal-nucleus	4
Anterior thalamic nuclei volume	4
aparc-a2009s lh area S-orbital-H-Shaped	4
aparc-a2009s lh thickness G-cuneus	4
aparc-a2009s lh thickness Pole-occipital	4
aparc-a2009s rh thickness G-cuneus	4
aparc-a2009s rh thickness G-oc-temp-med-Lingual	4
aparc-a2009s rh thickness Pole-occipital	4
aparc-Desikan lh thickness cuneus	4
aparc-Desikan lh thickness GlobalMeanThickness	4
aparc-Desikan lh thickness inferiortemporal	4
aparc-Desikan lh thickness lateraloccipital	4
aparc-Desikan lh thickness paracentral	4
aparc-Desikan lh thickness precentral	4
aparc-Desikan rh thickness cuneus	4
aparc-Desikan rh thickness GlobalMeanThickness	4
aparc-Desikan rh thickness lateraloccipital	4
aparc-Desikan rh thickness lingual	4
aparc-Desikan rh thickness paracentral	4
aparc-Desikan rh thickness pericalcarine	4
aparc-Desikan rh thickness transversetemporal	4
aparc-DKTatlas lh thickness cuneus	4
aparc-DKTatlas lh thickness lateraloccipital	4
aparc-DKTatlas lh thickness paracentral	4
aparc-DKTatlas lh thickness precentral	4
aparc-DKTatlas rh thickness cuneus	4
aparc-DKTatlas rh thickness lateraloccipital	4
aparc-DKTatlas rh thickness lingual	4
aparc-DKTatlas rh thickness paracentral	4
aparc-DKTatlas rh thickness pericalcarine	4
aparc-DKTatlas rh thickness transversetemporal	4
Arachidonate (20:4n6) levels	4
Arsenic metabolism	4
Ascending aorta maximum area (MTAG)	4
aseg lh intensity Cerebellum-Cortex	4
aseg lh intensity VentralDC	4
aseg lh volume Accumbens-area	4
aseg rh intensity Cerebellum-Cortex	4
Atopic asthma	4
Attention deficit hyperactivity disorder or cannabis use	4
Autism and major depressive disorder (MTAG)	4
Average diameter for LDL particles	4
Avocado liking	4
BA-exvivo lh thickness BA4a	4
BA-exvivo lh thickness BA4p	4
BA-exvivo lh thickness V2	4
BA-exvivo rh thickness BA4a	4
BA-exvivo rh thickness V1	4
BA-exvivo rh thickness V2	4
Body fat percentage and LDL-C (pairwise)	4
Body mass index and coronary artery disease (pairwise)	4
Body mass index and HDL-C (pairwise)	4
Brain shape (segment 2)	4
Brain shape (segment 20)	4
Brain surface area change rate x age interaction (2df)	4
Caffeine levels	4
Cancer	4
Cannabis dependence symptom count	4
Cardiorespiratory fitness (vo2 max)	4
Cathepsin D levels	4
Cathepsin S levels	4
Caudate nucleus volume	4
Cauliflower liking	4
Childhood gender nonconformity	4
Cholesterol	4
Cholesterol to total lipids ratio in chylomicrons and extremely large VLDL	4
Cholesteryl ester (15:0) levels	4
Cholesteryl ester (18:3) levels	4
Cholesteryl ester (20:2) levels	4
Cholesteryl ester (22:4) levels	4
Cholesteryl ester (22:5) (n3) levels	4
Cholesteryl ester (22:5) (n6) levels	4
Cholesteryl ester (24:4) levels	4
Cholesteryl ester 20:4 levels	4
Chronic kidney disease	4
Cognitive empathy	4
Colorectal cancer or advanced adenoma	4
Comprehensive strength and appendicular lean mass	4
Coriander liking	4
Coronary artery disease or factor VIII levels (pleiotropy)	4
Creatine kinase levels	4
Crohn's disease vs rheumatoid arthritis (ordinary least squares (OLS))	4
Cutaneous squamous cell carcinoma	4
Decaffeinated coffee consumption and/or alcohol consumption score	4
Decaffeinated coffee consumption and/or alcohol dependence and hazardous-use score	4
Decaffeinated coffee consumption and/or alcohol use disorder score	4
Dehydrocholesteryl ester (16:0) levels	4
Dehydrocholesteryl ester (20:4) levels	4
Dehydrocholesteryl ester (20:5) levels	4
Delta-6 desaturase activity	4
Descending thoracic aortic diameter	4
Diacylglycerol (16:0_20:4) levels	4
Diacylglycerol (18:0_20:4) levels	4
Diacylglycerol (18:2_20:4) levels	4
Diacylglycerol 38:4 levels	4
Diacylglycerol 38:5 levels	4
Dried fruit consumption	4
Drink temperature	4
Drinks usually with meals in current drinkers (yes and it varies vs no) (UKB data field 1618)	4
Esophageal cancer	4
Estradiol levels	4
Eye color	4
F-fruit liking (derived food-liking factor)	4
F-sweet food liking (derived food-liking factor)	4
F-whole food liking (derived food-liking factor)	4
Factor VII activity or levels	4
Factor VIII levels	4
Familial combined hyperlipidemia defined by Goldstein criteria	4
Family history of Alzheimer's disease	4
Fasting blood insulin adjusted for BMI	4
Fasting docosahexaenoic acid (22:6)	4
Fasting mean diameter of VLDLD particles	4
Fasting plasma glucose	4
Fibrinogen	4
Fibrosis-4 index in high alcohol intake	4
Free cholesterol levels	4
Glycated haemoglobin HbA1c levels adjusted for BMI	4
Glycemic traits (pleiotropy)	4
Glycemic traits (pregnancy)	4
Gout vs asymptomatic hyperuricemia	4
Gut microbiota abundance (class Actinobacteria id.419)	4
Handedness (left-handed vs. right-handed)	4
Handedness (non-right-handed vs right-handed)	4
High-grade serous ovarian cancer	4
Histidine levels	4
Hyperlipidemia	4
Hypertrophic cardiomyopathy (MTAG)	4
IDP dMRI ProbtrackX L1 ptr l	4
IDP dMRI ProbtrackX L2 atr l	4
IDP dMRI TBSS ICVF Anterior limb of internal capsule L	4
IDP dMRI TBSS ICVF Posterior limb of internal capsule R	4
IDP dMRI TBSS ICVF Superior fronto-occipital fasciculus L	4
IDP dMRI TBSS L1 Cerebral peduncle L	4
IDP dMRI TBSS L1 Cerebral peduncle R	4
IDP dMRI TBSS L1 External capsule L	4
IDP dMRI TBSS L1 Superior fronto-occipital fasciculus R	4
IDP dMRI TBSS L1 Superior longitudinal fasciculus L	4
IDP dMRI TBSS L1 Uncinate fasciculus L	4
IDP dMRI TBSS MD Cerebral peduncle L	4
IDP dMRI TBSS MD Superior corona radiata L	4
IDP dMRI TBSS MD Superior fronto-occipital fasciculus L	4
IDP dMRI TBSS MD Superior fronto-occipital fasciculus R	4
IDP dMRI TBSS OD Anterior limb of internal capsule R	4
IDP T1 FAST ROIs brain stem	4
IDP T1 FAST ROIs L caudate	4
IDP T1 FAST ROIs L cerebellum V	4
IDP T1 FAST ROIs L cerebellum VI	4
IDP T1 FAST ROIs R caudate	4
IDP T1 FAST ROIs R cerebellum VI	4
IDP T1 FAST ROIs V cerebellum X	4
Infant length	4
Information processing speed	4
Interleukin-12p70 levels	4
Invasive epithelial ovarian cancer	4
Iron status biomarkers (ferritin levels)	4
Iron status biomarkers (total iron binding capacity)	4
Isoleucine levels	4
Language functional connectivity	4
LDL cholesterol x physical activity interaction (2df test)	4
Left–right brain asymmetry	4
Leisure screen time (MTAG)	4
Liver fibrosis and steatohepatitis severity (MRI cT1 measure)	4
Liver volume	4
Local histogram emphysema pattern	4
Low myopia vs hyperopia	4
Lysoalkenylphosphatidylcholine (P-18:1) levels	4
Lysoalkenylphosphatidylcholine (P-20:0) levels	4
Lysoalkylphosphatidylcholine (O-20:0) levels	4
Lysoalkylphosphatidylcholine (O-22:0) levels	4
Lysoalkylphosphatidylcholine (O-24:0) levels	4
Lysoalkylphosphatidylcholine (O-24:2) levels	4
Lysophosphatidylcholine (18:3) [sn1] levels (b)	4
Lysophosphatidylcholine (18:3) [sn2] levels (a)	4
Lysophosphatidylcholine (20:2) [sn1] levels	4
Lysophosphatidylcholine (20:2) [sn2] levels	4
Lysophosphatidylcholine (20:4) [sn1] levels	4
Lysophosphatidylcholine (20:4) [sn2] levels	4
Lysophosphatidylcholine (20:5) [sn1] levels	4
Lysophosphatidylcholine (20:5) [sn2] levels	4
Lysophosphatidylcholine (22:4) [sn1] levels	4
Lysophosphatidylcholine (22:4) [sn2] levels	4
Lysophosphatidylcholine (22:5) [sn1] (n3) levels/Lysophosphatidylcholine (22:5) [sn2] (n6) levels	4
Lysophosphatidylcholine (22:5) [sn2] (n3) levels	4
Lysophosphatidylcholine (24:0) [sn1] levels	4
Lysophosphatidylcholine (24:0) [sn2] levels	4
Lysophosphatidylcholine (26:0) [sn1] levels	4
Lysophosphatidylcholine (26:0) [sn2] levels	4
lysoPhosphatidylcholine acyl C16:0 levels	4
lysoPhosphatidylcholine acyl C16:1 levels	4
lysoPhosphatidylcholine acyl C18:0 levels	4
lysoPhosphatidylcholine acyl C20:3 levels	4
Lysophosphatidylcholines (20:4) levels	4
Lysophosphatidylethanolamine (18:2) [sn1] levels	4
Lysophosphatidylethanolamine (18:2) [sn2] levels	4
Lysophosphatidylethanolamine (20:4) [sn2] levels	4
Lysophosphatidylethanolamine levels	4
Lysophosphatidylinositol (20:4) [sn1] levels	4
Lysophosphatidylinositol (20:4) [sn2] levels	4
Macular telangiectasia type 2	4
Mannose levels	4
Medication use (anti-inflammatory and antirheumatic products, non-steroids)	4
Milk chocolate liking	4
Mitochondrial DNA levels	4
Monocyte chemoattractant protein-1 levels	4
Multiple system atrophy	4
Myopia (age of diagnosis)	4
Nasal polyps	4
Non-lobar intracerebral hemorrhage (MTAG)	4
Nonalcoholic fatty liver disease (imputed)	4
NT-proBNP levels in acute coronary syndrome	4
Nucleus accumbens volume	4
Pancreatic cancer	4
Paraxanthine levels	4
Phosphatidylcholine (14:0_20:4) levels	4
Phosphatidylcholine (15-MHDA_18:2) levels	4
Phosphatidylcholine (15-MHDA_20:4) levels	4
Phosphatidylcholine (15:0_20:3) levels	4
Phosphatidylcholine (15:0_20:4) levels	4
Phosphatidylcholine (16:0_18:0) levels	4
Phosphatidylcholine (16:0_18:2) levels	4
Phosphatidylcholine (16:0_18:3) (a) levels	4
Phosphatidylcholine (16:0_20:3) (a) levels	4
Phosphatidylcholine (16:0_20:3) (b) levels	4
Phosphatidylcholine (16:0_20:4) levels	4
Phosphatidylcholine (16:0_20:5) levels	4
Phosphatidylcholine (16:1_20:4) levels	4
Phosphatidylcholine (17:0_20:4) levels	4
Phosphatidylcholine (17:1_18:2) levels	4
Phosphatidylcholine (18:0_20:4) levels	4
Phosphatidylcholine (18:0_22:4) levels	4
Phosphatidylcholine (18:0_22:5) (n3) levels/Phosphatidylcholine (20:1_20:4) levels	4
Phosphatidylcholine (18:1_18:1) levels	4
Phosphatidylcholine (18:1_20:3) levels	4
Phosphatidylcholine (18:1_22:6) (a) levels	4
Phosphatidylcholine (18:2_18:2) levels	4
Phosphatidylcholine (20:0_20:4) levels	4
Phosphatidylcholine (34:5) levels	4
Phosphatidylcholine (35:5) levels	4
Phosphatidylcholine (38:2) levels	4
Phosphatidylcholine (38:5) (a) levels	4
Phosphatidylcholine (38:5) (b) levels	4
Phosphatidylcholine (38:6) (a) levels	4
Phosphatidylcholine (39:5) (b) levels	4
Phosphatidylcholine (40:8) levels	4
Phosphatidylcholine 36:4 levels	4
Phosphatidylcholine 38:4 levels	4
Phosphatidylcholine acyl-alkyl C36:5 levels	4
Phosphatidylcholine acyl-alkyl C38:3 levels	4
Phosphatidylcholine acyl-alkyl C38:4 levels	4
Phosphatidylcholine acyl-alkyl C38:5 levels	4
Phosphatidylcholine acyl-alkyl C42:5 levels	4
Phosphatidylcholine diacyl C32:2 levels	4
Phosphatidylcholine diacyl C34:3 levels	4
Phosphatidylcholine diacyl C36:4 levels	4
Phosphatidylcholine diacyl C36:6 levels	4
Phosphatidylcholine diacyl C38:4 levels	4
Phosphatidylcholine diacyl C40:5 levels	4
Phosphatidylcholine diacyl C40:6 levels	4
Phosphatidylcholines (34:4) levels	4
Phosphatidylcholines (35:4) levels	4
Phosphatidylcholines (36:4)B levels	4
Phosphatidylcholines (37:5) levels	4
Phosphatidylcholines (38:5)A levels	4
Phosphatidylcholines (38:5)B levels	4
Phosphatidylcholines (40:8) levels	4
Phosphatidylethanolamine (15-MHDA_18:2) levels	4
Phosphatidylethanolamine (16:0_16:1) levels	4
Phosphatidylethanolamine (16:0_18:2) levels	4
Phosphatidylethanolamine (16:0_18:3) (a) levels	4
Phosphatidylethanolamine (16:0_20:3) levels	4
Phosphatidylethanolamine (16:1_18:2) levels	4
Phosphatidylethanolamine (17:0_18:2) levels	4
Phosphatidylethanolamine (18:0_18:2) levels	4
Phosphatidylethanolamine (18:0_20:3) (a) levels	4
Phosphatidylethanolamine (18:1_18:1) levels	4
Phosphatidylethanolamine (18:1_18:2) levels	4
Phosphatidylethanolamine (38:4)A levels	4
Phosphatidylethanolamine-ether levels	4
Phosphatidylglycerol-O_42:0_[M-H]1- levels	4
Phosphatidylinositol (15-MHDA_20:4) levels/Phosphatidylinositol (17:0_20:4) levels	4
Phosphatidylinositol (16:0_20:3) (a) levels	4
Phosphatidylinositol (16:0_20:4) levels	4
Phosphatidylinositol (18:0_20:2) levels	4
Phosphatidylinositol (18:0_20:3) (a) levels	4
Phosphatidylinositol (18:0_20:3) (b) levels	4
Phosphatidylinositol (18:0_20:4) levels	4
Phosphatidylinositol (18:0_22:5) (n6) levels	4
Phosphatidylserine (38:3) levels	4
Phospholipids to total lipids ratio in small HDL	4
Plasma lactate levels	4
Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid)	4
Postprandial docosahexaenoic acid (22:6)	4
Postprandial mean diameter of VLDLD particles	4
Poultry consumption	4
Primary biliary cholangitis	4
Protein C levels	4
Prothrombin time	4
Pulmonary fibrosis	4
Putamen volume	4
Pyruvate levels	4
QC SWI-to-T1 linear alignment discrepancy	4
QT dynamics during exercise	4
Renal overload gout	4
Response to statin therapy	4
Response to statins (LDL cholesterol change)	4
Salad dressing liking	4
Schizophrenia vs Tourette's syndrome and other tic disorders (ordinary least squares (OLS))	4
Serine levels	4
Serous invasive ovarian cancer	4
Serum levels of protein APOE	4
Serum urate levels in chronic kidney disease	4
Shoulder impingement or rotator cuff tear	4
Smoking status (heavy vs never)	4
Sociability score	4
Sphingolipid levels	4
Sphingomyelin (d18:2/22:0) levels	4
Sphingomyelin (d18:2/23:0) levels	4
Sphingomyelin (d18:2/24:0) levels	4
Sphingomyeline C16:0 levels	4
Sphingomyeline C18:0 levels	4
ST2 protein levels	4
Supranormal left ventricular ejection fraction	4
Testosterone levels in postmenopausal women	4
ThalamNuclei lh volume CM	4
ThalamNuclei lh volume PuI	4
ThalamNuclei rh volume MGN	4
ThalamNuclei rh volume PuI	4
ThalamNuclei rh volume VAmc	4
Total Alkenylphosphatidylcholine levels	4
Total Alkylphosphatidylcholine levels	4
Total Lysoalkylphosphatidylcholine levels	4
Triacylglycerol (56:6) [NL-20:4] levels	4
Triacylglycerol (56:8) [NL-20:4] levels	4
Turnip liking	4
Unstable angina pectoris	4
Vaccenic acid (18:1n-7) levels	4
Varicose veins	4
vWF levels	4
Warfarin maintenance dose	4
wg lh intensity-contrast caudalmiddlefrontal	4
wg lh intensity-contrast entorhinal	4
wg lh intensity-contrast inferiorparietal	4
wg lh intensity-contrast inferiortemporal	4
wg lh intensity-contrast paracentral	4
wg lh intensity-contrast parahippocampal	4
wg lh intensity-contrast parsopercularis	4
wg lh intensity-contrast posteriorcingulate	4
wg lh intensity-contrast precentral	4
wg lh intensity-contrast precuneus	4
wg lh intensity-contrast supramarginal	4
wg rh intensity-contrast entorhinal	4
wg rh intensity-contrast inferiorparietal	4
wg rh intensity-contrast isthmuscingulate	4
wg rh intensity-contrast paracentral	4
wg rh intensity-contrast parahippocampal	4
wg rh intensity-contrast precuneus	4
wg rh intensity-contrast superiorparietal	4
wg rh intensity-contrast supramarginal	4
Whole grain cereal liking	4
Worry/vulnerability (special factor of neuroticism)	4
1-linoleoyl-GPE (18:2) levels in elite athletes	3
Alanine transaminase levels	3
Alcohol liking	3
Alkenylphosphatidylcholine (P-18:0/22:6) levels	3
Alkenylphosphatidylethanolamine (P-18:0/18:1) levels	3
Alzheimer's disease or gastroesophageal reflux disease and/or peptic ulcer disease	3
Alzheimer's disease or HDL levels (pleiotropy)	3
Anorexia nervosa vs Tourette's syndrome and other tic disorders (ordinary least squares (OLS))	3
antipsychotic drug dosage in schizophrenia or schizoaffective disorder	3
Anxiety disorder (factor score)	3
aparc-Desikan lh volume pericalcarine	3
aparc-Desikan rh area fusiform	3
aparc-Desikan rh area pericalcarine	3
aparc-Desikan rh volume pericalcarine	3
aparc-DKTatlas lh volume pericalcarine	3
aparc-DKTatlas rh area fusiform	3
aparc-DKTatlas rh volume pericalcarine	3
aparc-pial rh area fusiform	3
aparc-pial rh area pericalcarine	3
Asthma onset (childhood vs adult)	3
Atrial fibrillation/atrial flutter	3
Attention deficit hyperactivity disorder (persistent)	3
Autism spectrum disorder vs Tourette's syndrome and other tic disorders (ordinary least squares (OLS))	3
Basophil percentage of white cells	3
Beer or cider consumption (glasses per month) (UKB data field 1578, 4420)	3
Bipolar disorder vs Tourette's syndrome and other tic disorders (ordinary least squares (OLS))	3
Bitter ale liking	3
Bitter taste perception (multivariate analysis)	3
Body fat percentage and coronary artery disease (pairwise)	3
Body fat percentage and HDL-C (pairwise)	3
Body fat percentage and triglycerides (pairwise)	3
Bone ultrasound measurement (broadband ultrasound attenuation)	3
Brain rsFMRI measurement (functional connectivity) (Net100_Pair15_45)	3
Brain rsFMRI measurement (functional connectivity) (Net100_Pair28_47)	3
Brain shape (segment 151)	3
Breakfast cereal skipping frequency	3
Breakfast skipping	3
Cardiac muscle measurement	3
Central corneal thickness	3
Cereal type: Other (e.g. Cornflakes, Frosties) (UKB data field 1468_5)	3
Cerebral aneurysm	3
Chloride levels	3
Cholecystitis	3
Cholesterol to total lipids ratio in small LDL	3
Cholesterol to total lipids ratio in very large HDL	3
Cholesterol_[M+H-H2O]1+ levels	3
Cholesteryl ester (18:2) levels	3
Cholesteryl ester_18:0_[M+NH4]1+ levels	3
Chronic obstructive pulmonary disease in non-current smokers	3
Chronic obstructive pulmonary disease or high blood pressure (pleiotropy)	3
Chronic obstructive pulmonary disease x current smoker interaction (2df)	3
Chronic obstructive pulmonary disease x current smoker interaction (main effect)	3
Cigarettes smoked per day (past)	3
Citrate levels	3
Cooked vegetable consumption	3
COVID-19 (covid vs negative)	3
Dehydrocholesteryl ester (18:2) levels	3
Excessive daytime sleepiness	3
Falling risk	3
Fasting total cholesterol in HDL	3
Fat body mass	3
Febrile seizures	3
Follistatin levels	3
Free thyroxine concentration	3
Fruit liking	3
Ganglion cell inner plexiform layer (GCIPL) thickness	3
Gout (combined type)	3
Granulocyte percentage of myeloid white cells	3
Help-seeking from a psychiatrist	3
Hirschsprung disease	3
HIV-1 susceptibility	3
Human milk oligosaccharide concentration (2'-fucosyllactose)	3
Hydroxycholesterol_[M+H-2H2O]1+ levels	3
Hydroxysphingomyeline C22:2 levels	3
Hyperuricemia	3
IDP dMRI ProbtrackX L1 slf l	3
IDP dMRI TBSS L3 Anterior corona radiata L	3
IDP dMRI TBSS L3 Superior fronto-occipital fasciculus L	3
IDP dMRI TBSS MD Posterior limb of internal capsule R	3
IGF-1 and IGFBP-3 levels (bivariate analysis)	3
Inflammatory skin disease	3
Interferon gamma-induced protein 10 levels	3
interferon-related traits	3
Ischemic stroke or factor VIII levels (pleiotropy)	3
Ischemic stroke or plasminogen activator inhibitor 1 levels (pleiotropy)	3
Ischemic stroke or tissue plasminogen activator levels (pleiotropy)	3
Itch intensity from mosquito bite adjusted by bite size	3
Kidney stones	3
Left ventricle wall thickness	3
Left ventricular mass	3
Left ventricular mass to end-diastolic volume ratio	3
lysoPhosphatidylcholine acyl C28:0 levels	3
Lysophosphatidylcholines (20:5) levels	3
Lysophosphatidylcholines (22:5) levels	3
Major depressive disorder or stroke (pleiotropy)	3
Melanoma	3
Middle temporal gyrus volume (24 month visit)	3
Migraine without aura	3
Mouth ulcers	3
Mucinous adenocarcinoma in colorectal cancer	3
Neuronal growth regulator 1 levels	3
Nevus count or cutaneous melanoma	3
Nonatopic asthma or type 2 diabetes	3
Oral cavity and pharyngeal cancer	3
OTU97_8 (Ruminococcaceae) prevalence	3
Pappalysin-1 levels	3
Pericardial adipose tissue adjusted for height and weight	3
Peripheral artery disease in ever smokers	3
Phosphatidylcholine (18:0_22:5) (n6) levels	3
Phosphatidylcholine-O_36:1_[M+H]1+/Phosphatidylcholine-P_36:0_[M+H]1+/Phosphatidylethanolamine-O_39:1_[M+H]1+ levels	3
Phosphatidylcholine(38:2)_[M+H]1+/Phosphatidylethanolamine(41:2)_[M+H]1+ levels	3
Phosphatidylcholines (36:5)C levels	3
Phosphatidylglycerol-O_40:0_[M-H]1- levels	3
Phospholipid levels (plasma)	3
Platelet-derived growth factor subunit B levels	3
Plum liking	3
Post-traumatic stress disorder (MTAG)	3
Posterior cortical atrophy and Alzheimer's disease	3
Principal component-derived dietary pattern 18	3
Principal component-derived dietary pattern 4	3
Principal component-derived dietary pattern 7	3
Prostate cancer (advanced)	3
QT interval (drug interaction)	3
Red blood cell traits	3
Regular attendance at a religious group	3
Retinal nerve fibre layer thickness or ganglion cell inner plexiform layer thickness (MTAG)	3
Retinal vascular caliber	3
Rheumatoid arthritis (ACPA-positive)	3
Salty food liking	3
Sarcoidosis	3
Serum levels of protein ISLR2	3
Serum levels of protein NEGR1	3
Serum total cholesterol levels	3
Sleep traits (multi-trait analysis)	3
Small cell lung carcinoma	3
Social science traits (pleiotropy) (HIPO component 1)	3
Sphingomyelin_39:1_[M+H]1+ levels	3
Sphingomyelin_40:0_[M+H]1+ levels	3
Sphingomyelin_40:1_[M+H]1+ levels	3
Sphingomyelin_41:0_[M+H]1+ levels	3
Spleen volume	3
Spontaneous coronary artery dissection	3
Succinylcarnitine (C4-DC) levels in elite athletes	3
Testosterone levels in premenopausal women	3
Total Cholesteryl ester levels	3
Total concentration of branched-chain amino acids (leucine + isoleucine + valine)	3
Total intracranial volume	3
Total Phosphatidylcholine levels	3
Triacylglycerol_45:4_[M+NH4]1+ levels	3
Triacylglycerol_46:4_[M+NH4]1+ levels	3
Triacylglycerol_47:4_[M+NH4]1+ levels	3
Triglyceride levels in HIV infection	3
Triglycerides (56:9) levels	3
Triglycerides (58:10) levels	3
Trihexosylcermide (d18:1/24:0) levels	3
Tumor necrosis factor ligand superfamily member 6, soluble form levels	3
Type 2 diabetes or prostate cancer (pleiotropy)	3
Urate levels in lean individuals	3
Urinary creatinine levels	3
Urinary metabolite modules (eigenmetabolites) in chronic kidney disease	3
Valine levels	3
Vertical cup-disc ratio	3
Vitamin B levels in ischemic stroke	3
Waist circumference and related phenotypes	3
Waist-hip ratio and coronary artery disease (pairwise)	3
Waist-hip ratio and HDL-C (pairwise)	3
Waist-hip ratio and LDL-C (pairwise)	3
Waist-hip ratio and triglycerides (pairwise)	3
1-(1-enyl-palmitoyl)-2-arachidonoyl-gpc (p-16:0/20:4) levels	2
1-(1-enyl-palmitoyl)-2-arachidonoyl-GPC (P-16:0/20:4) levels in elite athletes	2
1-(1-enyl-palmitoyl)-2-arachidonoyl-GPE (p-16:0/20:4) levels	2
1-(1-enyl-palmitoyl)-GPC (p-16:0) levels	2
1-(1-enyl-stearoyl)-2-arachidonoyl-GPC (p-18:0/20:4) levels	2
1-(1-enyl-stearoyl)-2-arachidonoyl-GPE (p-18:0/20:4) levels	2
1-adrenoyl-GPC (22:4) levels	2
1-arachidonoyl-GPC (20:4n6) levels in elite athletes	2
1-arachidonoyl-GPE (20:4n6) levels	2
1-arachidonoyl-GPI (20:4) levels	2
1-arachidonoylglycerophosphocholine levels (Biocrates platform)	2
1-arachidonoylglycerophosphocholine levels (Metabolon platform)	2
1-arachidonylglycerol (20:4) levels	2
1-carboxyethylisoleucine levels	2
1-carboxyethylleucine levels	2
1-carboxyethylphenylalanine levels	2
1-carboxyethylvaline levels	2
1-dihomo-linolenoyl-GPE (20:3n3 or 6) levels	2
1-dihomo-linoleoyl-GPC (20:2) levels	2
1-docosapentaenoyl-GPC (22:5n3) levels	2
1-eicosapentaenoyl-GPC (20:5) levels	2
1-eicosapentaenoyl-GPE (20:5) levels	2
1-linolenoyl-GPE (18:3) levels	2
1-linoleoyl-2-arachidonoyl-GPC (18:2/20:4n6) levels	2
1-linoleoyl-2-linolenoyl-GPC (18:2/18:3) levels	2
1-linoleoyl-GPE (18:2) levels	2
1-linoleoyl-GPI (18:2) levels	2
1-linoleoylglycerophosphoethanolamine levels	2
1-margaroyl-2-linoleoyl-GPC (17:0/18:2) levels	2
1-meadoyl-GPC (20:3n9) levels	2
1-myristoyl-2-docosahexaenoyl-GPC (14:0/22:6) levels	2
1-myristoyl-2-eicosapentaenoyl-GPC (14:0/20:5) levels	2
1-myristoyl-2-linoleoyl-GPC (14:0/18:2) levels	2
1-myristoyl-GPC (14:0) levels	2
1-myristoylglycerol (14:0) levels	2
1-oleoyl-2-dihomo-linolenoyl-GPC (18:1/20:3) levels	2
1-oleoyl-2-docosahexaenoyl-GPE (18:1/22:6) levels	2
1-oleoyl-2-eicosapentaenoyl-GPC (18:1/20:5) levels	2
1-oleoyl-2-linoleoyl-GPE (18:1/18:2) levels	2
1-palmitoleoyl-2-linolenoyl-GPC (16:1/18:3) levels	2
1-palmitoleoylglycerol (16:1) levels	2
1-palmitoyl-2-arachidonoyl-GPC (16:0/20:4n6) levels in elite athletes	2
1-palmitoyl-2-dihomo-linolenoyl-GPE (16:0/20:3) levels	2
1-palmitoyl-2-eicosapentaenoyl-GPC (16:0/20:5) levels	2
1-palmitoyl-2-linoleoyl-gpc (16:0/18:2) levels	2
1-palmitoyl-2-linoleoyl-GPE (16:0/18:2) levels	2
1-palmitoyl-2-linoleoyl-GPI (16:0/18:2) levels	2
1-palmitoyl-2-meadoyl-GPC (16:0/20:3n9) levels	2
1-palmitoyl-2-oleoyl-GPE (16:0/18:1) levels	2
1-palmitoyl-2-oleoyl-GPI (16:0/18:1) levels	2
1-palmitoyl-2-stearoyl-gpc (16:0/18:0) levels	2
1-palmitoyl-GPE (16:0) levels	2
1-palmityl-2-arachidonoyl-GPC (o-16:0/20:4) levels	2
1-pentadecanoyl-2-arachidonoyl-GPC (15:0/20:4) levels	2
1-pentadecanoyl-2-linoleoyl-GPC (15:0/18:2) levels	2
1-stearoyl-2-adrenoyl-GPC (18:0/22:4) levels	2
1-stearoyl-2-arachidonoyl-GPC (18:0/20:4) levels in elite athletes	2
1-stearoyl-2-docosahexaenoyl-GPE (18:0/22:6) levels	2
1-stearoyl-2-linoleoyl-gpc (18:0/18:2) levels	2
1-stearoyl-2-linoleoyl-GPI (18:0/18:2) levels	2
1-stearoyl-2-meadoyl-GPC (18:0/20:3n9) levels	2
1-stearoyl-2-oleoyl-GPI (18:0/18:1) levels	2
1-stearoyl-GPE (18:0) levels	2
1,2-dilinoleoyl-GPC (18:2/18:2) levels	2
1,2-dipalmitoyl-gpc (16:0/16:0) levels	2
1,3,7-trimethylurate levels	2
1,5-anhydroglucitol levels	2
1,7-dimethylurate levels	2
2-arachidonoyl-GPC (20:4) levels	2
2-linoleoyl-GPE (18:2) levels	2
2-myristoyl-GPC (14:0) levels	2
3-aminoisobutyrate levels	2
3-methylxanthine levels	2
3,5-dichloro-2,6-dihydroxybenzoic acid levels	2
6-hydroxyindole sulfate levels	2
Academic attainment (science)	2
acne vulgaris	2
Activated partial thromboplastin time	2
Added salt consumption	2
ADHD vs anorexia nervosa (ordinary least squares (OLS))	2
Adrenate (22:4n6) levels	2
Adult diffuse glioma (IDH mutation)	2
Adult onset asthma or fasting glucose levels	2
Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs)	2
Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin)	2
Age of smoking initiation	2
Age-related hearing impairment (SNP x SNP interaction)	2
Airflow obstruction	2
Alkenylphosphatidylcholine (P-15:0/20:4) (a) levels	2
Alkenylphosphatidylcholine (P-16:0/16:0) levels	2
Alkenylphosphatidylcholine (P-16:0/18:0) levels	2
Alkenylphosphatidylcholine (P-16:0/18:3) levels	2
Alkenylphosphatidylcholine (P-16:0/20:5) levels	2
Alkenylphosphatidylcholine (P-16:0/22:6) levels	2
Alkenylphosphatidylcholine (P-36:3) levels	2
Alkenylphosphatidylethanolamine (P-16:0/18:1) levels	2
Alkenylphosphatidylethanolamine (P-16:0/18:2) levels	2
Alkenylphosphatidylethanolamine (P-16:0/18:3) levels	2
Alkenylphosphatidylethanolamine (P-18:0/18:2) levels	2
Alkenylphosphatidylethanolamine (P-18:0/18:3) levels	2
Alkenylphosphatidylethanolamine (P-18:0/22:5) (n6) levels	2
Alkenylphosphatidylethanolamine (P-18:1/18:1) (a) levels	2
Alkenylphosphatidylethanolamine (P-18:1/18:1) (b) levels	2
Alkenylphosphatidylethanolamine (P-18:1/18:1) levels	2
Alkenylphosphatidylethanolamine (P-18:1/18:2) (a) levels	2
Alkenylphosphatidylethanolamine (P-18:1/18:2) (b) levels	2
Alkenylphosphatidylethanolamine (P-18:1/18:3) levels	2
Alkylphosphatidylcholine (O-16:0/22:6) levels	2
Alkylphosphatidylcholine (O-18:0/18:2) levels	2
Alkylphosphatidylcholine (O-18:1/18:1) levels	2
Alkylphosphatidylcholine (O-18:1/18:2) levels	2
Alkylphosphatidylcholine (O-32:1) levels	2
Alkylphosphatidylcholine (O-32:2) levels	2
Alkylphosphatidylcholine (O-34:1) levels	2
Alkylphosphatidylcholine (O-34:2) levels	2
Alkylphosphatidylcholine (O-34:4) levels	2
Alkylphosphatidylethanolamine (O-16:0/18:2) levels	2
Alkylphosphatidylethanolamine (O-18:1/18:2) levels	2
Alkylphosphatidylethanolamine (O-34:1) levels	2
Alzheimer's disease or peptic ulcer disease	2
Ambidextrousness	2
Androgen levels	2
Aniseed liking	2
Anorexia nervosa	2
Aortic valve stenosis	2
Apolipoprotein Levels	2
Arachidonoylcholine levels	2
Ascending aorta distensibility (MTAG)	2
Asparagine levels	2
Asthma (time to event)	2
Attention deficit hyperactivity disorder or autism spectrum disorder (pleiotropy)	2
Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)	2
Autoimmune traits	2
Basal cell carcinoma	2
Behcet's disease	2
Beta-citrylglutamate levels	2
Biological age (PhenoAge)	2
Birth length	2
BK polyomavirus VP1 antibody levels	2
Blood osmolality (transformed sodium)	2
Blood pressure (smoking interaction)	2
Blood sugar levels	2
Brain shape (segment 285)	2
Brainstem volume	2
Branched-chain amino acid levels (Isoleucine)	2
Branched-chain amino acid levels (Leucine)	2
Branched-chain amino acid levels (Valine)	2
Bread type: White vs wholemeal/wholegrain and brown (UKB data field 1448)	2
Breast cancer (estrogen-receptor positive)	2
Breast milk fatty acid composition (infant genotype effect)	2
Breast milk fatty acid composition (maternal genotype effect)	2
C-X-C motif chemokine 1 levels	2
Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) level)	2
Caffeine metabolism (plasma 3,7-dimethylxanthine (theobromine) level)	2
Capers liking	2
Cardiometabolic and hematological traits	2
CD19 on B cell	2
CD19 on switched memory B cell	2
Ceramide (d16:1/24:1, d18:1/22:1) levels	2
Ceramide (d18:1/20:0, d16:1/22:0, d20:1/18:0) levels	2
Ceramide (d18:1/24:0) levels	2
Ceramide (d18:1/24:1) levels	2
Cereal consumption (bowls per week) (UKB data field 1458)	2
Champagne or white wine consumption (glasses per month) (UKB data field 1578, 4418)	2
Childhood absence epilepsy	2
Childhood aggressive behavior	2
Chitinase-3-like protein 1 levels	2
Cholesteryl ester (20:1) levels	2
Cholesteryl ester (22:6) levels	2
Cholesteryl ester (24:5) levels	2
Cholesteryl ester 22:4 levels	2
Cholesteryl ester_15:0_[M+NH4]1+ levels	2
Cholesteryl esters to total lipids ratio in very large HDL	2
Chronic obstructive pulmonary disease in ever smokers	2
Chronic obstructive pulmonary disease in never smokers	2
Chronic obstructive pulmonary disease x ever smoker interaction (2df)	2
Chronic obstructive pulmonary disease x ever smoker interaction (main effect)	2
Circulating leptin levels or fasting insulin levels	2
Circulating leptin levels or HOMA-IR	2
Circulating leptin levels or type 2 diabetes	2
Cis-5,8,11,14,17-eicosapentaenoic acid (C20:5n3) levels in coronary artery disease	2
Clozapine concentration in schizophrenia	2
Coagulation factor IX levels	2
Coagulation factor IXab levels	2
Cognitive performance (attention) (longitudinal)	2
Cold sores	2
Colon polyp	2
Colorectal or endometrial cancer	2
Corneal resistance factor	2
Coronary artery disease and total cholesterol levels (multivariate analysis)	2
Coronary artery disease or ischemic stroke	2
Coronary artery disease or large artery stroke	2
Cotinine levels in current smokers	2
COVID-19 or hypertension (pleiotropy)	2
COVID-19 or obesity (pleiotropy)	2
Crohn's disease or Leprosy (opposite effect)	2
Cryptic phenotype that captures Alport syndrome severity	2
Cutaneous malignant melanoma	2
Cutaneous mastocytosis	2
Cutaneous melanoma or hair colour	2
Cytokine levels	2
Cytokine network levels (multivariate analysis)	2
Dehydrocholesteryl ester (22:6) levels	2
Dehydroepiandrosterone sulphate levels	2
Delta-5 desaturase activity response to n3-polyunsaturated fat supplement	2
Developmental dysplasia of the hip	2
DG(38:5) levels	2
Diacylglycerol (16:0_22:5) levels	2
Diacylglycerol (16:0_22:6) levels	2
Diacylglycerol (18:1_18:3) levels	2
Diacylglycerol_34:1_[M+H-H2O]1+ levels	2
Dickkopf-related protein 1 levels	2
Diffusing capacity of carbon monoxide	2
DNA methylation variation (age effect)	2
Docosapentaenoate (n3 DPA; 22:5n3) levels	2
Dried fruit liking	2
Drug experimentation measurement	2
Eicosapentaenoate (EPA; 20:5n3) levels	2
Eicosapentaenoylcholine levels	2
Electrocardiographic traits (multivariate)	2
End-stage coagulation	2
Endometriosis	2
Eotaxin levels	2
Epilepsy and lamotrigine-induced maculopapular eruptions	2
Episodic memory (pairs-matching)	2
Erectile dysfunction	2
Eudaimonic well-being	2
Extraversion	2
F-lentils/beans liking (derived food-liking factor)	2
F-low caloric food liking (derived food-liking factor)	2
Factor VII levels	2
Fasting apolipoprotein A-I	2
Fasting blood insulin (BMI interaction)	2
Fasting cholesterol esters in large HDL	2
Fasting cholesterol esters in very large HDL	2
Fasting estimated degree of unsaturation	2
Fasting free cholesterol in large HDL	2
Fasting free cholesterol in very large HDL	2
Fasting glycoprotein acetyls (mainly a1-acid glycoprotein)	2
Fasting insulin adjusted for BMI	2
Fasting isoleucine	2
Fasting large HDL particle concentration	2
Fasting mean diameter of HDL particles	2
Fasting phospholipid levels in large HDL	2
Fasting phospholipid levels in very large HDL	2
Fasting total cholesterol in HDL2	2
Fasting total cholesterol in HDL3	2
Fasting total cholesterol in large HDL	2
Fasting total cholesterol in very large HDL	2
Fasting total lipids in large HDL	2
Fasting total lipids in very large HDL	2
Fasting triglycerides levels in medium HDL	2
Fasting very large HDL particle concentration	2
Fatty acid desaturase activity (adipose tissue)	2
Fatty acid desaturase activity (serum)	2
Folate pathway vitamin levels	2
Fuchs's corneal dystrophy	2
G_Porphyromonadaceae prevalence	2
Galanin peptide levels	2
Gestational insulin sensitivity	2
Glioblastoma	2
Glioma	2
Glomerular filtration rate in non diabetics (creatinine)	2
Glucokinase regulatory protein levels	2
Glucose homeostasis traits	2
Glycemic traits (multi-trait analysis)	2
Gout vs. Hyperuricemia	2
Grapefruit liking	2
Gut microbiota (bacterial taxa, rank normal transformation method)	2
Gut microbiota (beta diversity)	2
Gut microbiota (functional units)	2
Head circumference (infant)	2
Heart rate	2
Heart rate response to recovery post exercise (10 sec)	2
Heart rate response to recovery post exercise (20 sec)	2
Heat shock protein beta-1 levels	2
Hedonic well-being	2
Help-seeking from a GP (without major depressive disorder symptoms)	2
Hematological and biochemical traits	2
Hematology traits	2
High myopia	2
High-density lipoprotein 3 cholesterol levels	2
Hippocampal tail volume (corrected for total hippocampal volume)	2
Homeostasis model assessment of beta-cell function	2
Homeostasis model assessment of insulin resistance	2
Homocysteine levels	2
Hydroxypalmitoyl sphingomyelin (d18:1/16:0(OH)) levels	2
Hyperthyroidism	2
IDP dMRI ProbtrackX L1 atr r	2
IDP dMRI TBSS ICVF Posterior limb of internal capsule L	2
IDP dMRI TBSS ICVF Retrolenticular part of internal capsule R	2
IDP dMRI TBSS L3 Superior fronto-occipital fasciculus R	2
IDP SWI T2star right putamen	2
IgA levels	2
Immunoglobulin superfamily containing leucine-rich repeat protein 2 levels	2
Indolin-2-one levels	2
Infant head circumference (MTAG)	2
Inflammatory biomarkers (multivariate analysis)	2
Inflammatory bowel disease (early onset)	2
Insulin-related traits (multivariate analysis)	2
Interferon gamma levels	2
Interleukin-10 levels	2
Interleukin-6 levels	2
Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy)	2
Intrahepatic cholestasis of pregnancy	2
Iron status biomarkers (transferrin levels)	2
Iron status biomarkers (transferrin saturation)	2
Ischemic stroke or factor XI levels (pleiotropy)	2
Ischemic stroke or von Willebrand factor levels (pleiotropy)	2
Lactosyl-N-behenoyl-sphingosine (d18:1/22:0) levels in elite athletes	2
Lactosyl-N-nervonoyl-sphingosine (d18:1/24:1) levels in elite athletes	2
Lacunar stroke	2
Lamb or mutton consumption (UKB data field 1379)	2
Large artery stroke	2
Laryngeal squamous cell carcinoma	2
LDL cholesterol levels in HIV infection	2
Left ventricular end-diastolic volume	2
Linoleoyl-arachidonoyl-glycerol (18:2/20:4) [1] levels	2
Low-density lipoprotein receptor-related protein 1B levels	2
Lysoalkenylphosphatidylethanolamine (P-20:0) levels	2
Lysoalkylphosphatidylcholine (O-18:1) levels	2
Lysoalkylphosphatidylcholine (O-20:1) levels	2
Lysoalkylphosphatidylcholine (O-22:1) levels	2
Lysoalkylphosphatidylcholine (O-24:1) levels	2
Lysophosphatidylcholine (17:0) [sn1] levels	2
Lysophosphatidylcholine (18:0) [sn1] levels	2
Lysophosphatidylcholine (18:0) [sn2] levels	2
Lysophosphatidylcholine (18:2) [sn1] levels	2
Lysophosphatidylcholine (18:2) [sn2] levels	2
Lysophosphatidylcholine (18:3) [sn1] (a) levels/Lysophosphatidylcholine (18:3) [sn2] (b) levels	2
Lysophosphatidylcholine (22:0) [sn1] levels	2
Lysophosphatidylcholine (22:1) [sn1] levels	2
Lysophosphatidylcholine (22:5) [sn1] (n6) levels	2
Lysophosphatidylcholine (22:6) [sn1] levels	2
Lysophosphatidylcholine (22:6) [sn2] levels	2
lysoPhosphatidylcholine acyl C14:0 levels	2
lysoPhosphatidylcholine acyl C18:2 levels	2
lysoPhosphatidylcholine acyl C20:4 levels	2
lysoPhosphatidylcholine acyl C24:0 levels	2
Lysophosphatidylcholine levels	2
Lysophosphatidylcholine_18:2_[M+OAc]1-/Lysophosphatidylserine_22:1_[M-H]1- levels	2
Lysophosphatidylethanolamine (18:1) [sn1] levels	2
Lysophosphatidylethanolamine (18:1) [sn2] levels	2
Lysophosphatidylethanolamine_20:2_[M-H]1- levels	2
Lysophosphatidylinositol (18:0) [sn1] levels	2
Lysophosphatidylinositol (18:2) [sn1] levels	2
Lysophosphatidylinositol (18:2) [sn2] levels	2
Major depressive disorder (ICD-10 coded)	2
Mammographic density (dense area)	2
Mannonate levels	2
Mean arterial pressure x educational attainment (graduated college) interaction (2df)	2
Medication use (antiglaucoma preparations and miotics)	2
Medication use (antimigraine preparations)	2
Menopause (age at onset)	2
Metabolic syndrome (multivariate analysis)	2
Metabolically unhealthy in normal weight	2
Metabolite peak levels (QI15536)	2
Metabolite peak levels (QI15965)	2
Metabolite peak levels (QI261)	2
Metabolite peak levels (QI4680)	2
Metabolite peak levels (QI6523)	2
Metabolite peak levels (QI6693)	2
Metabolite peak levels (QI6703)	2
Metabolite peak levels (QI6721)	2
Metabolite peak levels (QI9489)	2
MHC class I polypeptide-related sequence A levels	2
Migraine - clinic-based	2
Mitral valve prolapse	2
Motion sickness	2
MSP plasma levels	2
Mucinous ovarian carcinoma	2
Myopia	2
Myristoyl-linoleoyl-glycerol (14:0/18:2) [1] levels	2
NADPH--cytochrome P450 reductase levels	2
Neural cell adhesion molecule 1, 120 kDa isoform levels	2
Neuroblastoma	2
Neurofibrillary tangles (SNP x SNP interaction)	2
Neurological blood protein biomarker levels	2
Never eat sugar vs no sugar restrictions (UKB data field 6144)	2
Nisinate (24:6n3) levels	2
Nonalcoholic steatohepatitis	2
Nonatopic asthma or fasting glucose levels	2
Nonsyndromic orofacial cleft x sex interaction	2
Nonsyndromic orofacial cleft x sex interaction (2df)	2
Number of children ever born	2
Oleoyl-arachidonoyl-glycerol (18:1/20:4) [2] levels	2
Oleoyl-linoleoyl-glycerol (18:1/18:2) [1] levels	2
Oleoyl-linoleoyl-glycerol (18:1/18:2) [2] levels	2
Oleoyl-oleoyl-glycerol (18:1/18:1)  [1] levels	2
Optic disc size	2
Orofacial clefts	2
Other polyunsaturated fatty acid levels than 18:2	2
OTU97_51 (Barnesiella) abundance	2
OTU99_106 (Barnesiella) abundance	2
Oxidized cholesteryl ester (18:2) [+O] levels	2
P wave duration	2
Palmitic acid (16:0) levels	2
Palmitoleoyl-linoleoyl-glycerol (16:1/18:2) [1] levels	2
Pediatric asthma	2
Pelvic organ prolapse (moderate/severe)	2
Peptic ulcer disease	2
Percent glycated albumin	2
Percent mammographic density	2
Peripheral artery disease in non diabetes	2
Phosphatidate(43:6)_[M-H]1- levels	2
Phosphatidylcholine (14:0_22:6) levels	2
Phosphatidylcholine (15-MHDA_18:1) levels	2
Phosphatidylcholine (15:0_22:6) levels	2
Phosphatidylcholine (16:0_22:6) levels	2
Phosphatidylcholine (16:0/22:5n3, 18:1/20:4) levels	2
Phosphatidylcholine (17:0_18:2) levels	2
Phosphatidylcholine (17:0_22:6) levels	2
Phosphatidylcholine (18:0_18:2) levels	2
Phosphatidylcholine (18:0_22:6) levels	2
Phosphatidylcholine (18:0/20:2, 20:0/18:2) levels	2
Phosphatidylcholine (18:0/20:5, 16:0/22:5n6) levels	2
Phosphatidylcholine (18:1_18:2) levels	2
Phosphatidylcholine (18:2_20:5) levels	2
Phosphatidylcholine (32:2) levels	2
Phosphatidylcholine (33:0) (b) levels	2
Phosphatidylcholine (33:1) levels	2
Phosphatidylcholine (33:2) levels	2
Phosphatidylcholine (36:6) (a) levels	2
Phosphatidylcholine (38:7) (c) levels	2
Phosphatidylcholine (39:5) (a) levels	2
Phosphatidylcholine (O-18:1/20:4, O-16:0/22:5n3) levels	2
Phosphatidylcholine 34:4 levels	2
Phosphatidylcholine 36:3 levels	2
Phosphatidylcholine 38:2 levels	2
Phosphatidylcholine acyl-alkyl C30:1 levels	2
Phosphatidylcholine acyl-alkyl C30:2 levels	2
Phosphatidylcholine acyl-alkyl C34:2 levels	2
Phosphatidylcholine acyl-alkyl C36:2 levels	2
Phosphatidylcholine acyl-alkyl C36:3 levels	2
Phosphatidylcholine acyl-alkyl C36:4 levels	2
Phosphatidylcholine acyl-alkyl C38:0 levels	2
Phosphatidylcholine acyl-alkyl C38:1 levels	2
Phosphatidylcholine acyl-alkyl C38:2 levels	2
Phosphatidylcholine acyl-alkyl C38:6 levels	2
Phosphatidylcholine acyl-alkyl C40:1 levels	2
Phosphatidylcholine acyl-alkyl C40:3 levels	2
Phosphatidylcholine acyl-alkyl C40:5 levels	2
Phosphatidylcholine acyl-alkyl C40:6 levels	2
Phosphatidylcholine acyl-alkyl C42:2 levels	2
Phosphatidylcholine acyl-alkyl C42:3 levels	2
Phosphatidylcholine acyl-alkyl C42:4 levels	2
Phosphatidylcholine acyl-alkyl C44:5 levels	2
Phosphatidylcholine acyl-alkyl C44:6 levels	2
Phosphatidylcholine diacyl C24:0 levels	2
Phosphatidylcholine diacyl C26:0 levels	2
Phosphatidylcholine diacyl C30:0 levels	2
Phosphatidylcholine diacyl C32:0 levels	2
Phosphatidylcholine diacyl C32:1 levels	2
Phosphatidylcholine diacyl C34:1 levels	2
Phosphatidylcholine diacyl C34:2 levels	2
Phosphatidylcholine diacyl C36:2 levels	2
Phosphatidylcholine diacyl C36:3 levels	2
Phosphatidylcholine diacyl C36:5 levels	2
Phosphatidylcholine diacyl C38:0 levels	2
Phosphatidylcholine diacyl C38:6 levels	2
Phosphatidylcholine diacyl C40:2 levels	2
Phosphatidylcholine diacyl C40:4 levels	2
Phosphatidylcholine diacyl C42:0 levels	2
Phosphatidylcholine diacyl C42:1 levels	2
Phosphatidylcholine diacyl C42:4 levels	2
Phosphatidylcholine diacyl C42:6 levels	2
Phosphatidylcholine plasmalogen 36:5 levels	2
Phosphatidylcholines (36:3)B levels	2
Phosphatidylcholines (36:5)B levels	2
Phosphatidylcholines (37:4) levels	2
Phosphatidylcholines (38:4)A levels	2
Phosphatidylcholines (38:4)B levels	2
Phosphatidylcholines (38:4)C levels	2
Phosphatidylcholines (38:6)A levels	2
Phosphatidylcholines (39:4) levels	2
Phosphatidylcholines (40:6)A levels	2
Phosphatidylethanolamine (15-MHDA_18:1) levels	2
Phosphatidylethanolamine (16:0_18:1) levels	2
Phosphatidylethanolamine (16:0_18:3) (b) levels	2
Phosphatidylethanolamine (17:0_18:1) levels	2
Phosphatidylethanolamine (18:0_18:1) levels	2
Phosphatidylethanolamine (18:0_20:4) levels	2
Phosphatidylethanolamine (18:1_22:6) (a) levels	2
Phosphatidylethanolamine levels	2
Phosphatidylethanolamine_34:1_[M-H]1- levels	2
Phosphatidylglycerol-O_38:0_[M-H]1- levels	2
Phosphatidylinositol (15-MHDA_18:1) levels/Phosphatidylinositol (17:0_18:1) levels	2
Phosphatidylinositol (15-MHDA_18:2) levels/Phosphatidylinositol (17:0_18:2) levels	2
Phosphatidylinositol (16:0_16:1) levels	2
Phosphatidylinositol (18:0_18:1) levels	2
Phosphatidylinositol (18:1_18:2) levels	2
Phosphatidylinositol (34:1) levels	2
Phosphatidylinositol (36:2) levels	2
Phosphatidylserine-O_42:6_[M+H]1+ levels	2
Pizza liking	2
Plasma ANGPTL8 levels	2
Plasma clozapine levels in treatment-resistant schizophrenia	2
Plasma letrozole concentrations in letrozole treated hormone-receptor-positive breast cancer	2
Platelet-activating factor levels	2
Post-traumatic stress disorder	2
Postprandial cholesterol esters in very large HDL	2
Postprandial estimated degree of unsaturation	2
Postprandial free cholesterol in very large HDL	2
Postprandial glycoprotein acetyls (mainly a1-acid glycoprotein)	2
Postprandial isoleucine	2
Postprandial leucine	2
Postprandial mean diameter of HDL particles	2
Postprandial omega-3 fatty acids	2
Postprandial phospholipid levels in very large HDL	2
Postprandial total cholesterol in HDL	2
Postprandial total cholesterol in HDL2	2
Postprandial total cholesterol in HDL3	2
Postprandial total cholesterol in very large HDL	2
Postprandial total lipids in very large HDL	2
Postprandial triglycerides levels in medium HDL	2
Postprandial very large HDL particle concentration	2
Principal component-derived dietary pattern 43	2
Proheparin-binding EGF-like growth factor levels	2
Proteasome activator complex subunit 1 levels	2
Protein FAM3D levels	2
Protein levels in obesity	2
Proteinase-activated receptor 1 levels	2
Psoriasis vulgaris	2
Psychosis and Alzheimer's disease	2
Psychosis in Alzheimer's disease	2
Pubertal anthropometrics	2
Pulse pressure x alcohol consumption (light vs heavy) interaction (2df test)	2
QRS interval (sulfonylurea treatment interaction)	2
Quinone oxidoreductase-like protein 1 levels	2
R-6-hydroxywarfarin to R-warfarin ratio	2
Rate of ventricular enlargement	2
Ratio of bis-allylic bonds to double bonds in lipids	2
Red blood cell traits (multivariate analysis)	2
Renal cell carcinoma	2
Response to inhaled glucocorticoid treatment in asthma (change in FEV1)	2
Resting metabolic rate	2
Retinal nerve fibre layer (RNFL) thickness	2
Retinal vascular fractal density	2
Right ventricular end systolic volume	2
Right ventricular stroke volume (MTAG)	2
Rubella	2
same-sex sexual behaviour	2
Schizophrenia or bipolar disorder	2
Secreted and transmembrane protein 1 levels	2
Self-reported allergy	2
Sensory disturbances after bilateral sagittal split ramus osteotomy	2
Serum alpha1-antitrypsin levels	2
Serum chromium levels	2
Serum docosahexaenoic fatty acid concentration in metabolic syndrome	2
Serum glutamic-oxaloacetic transaminase levels	2
Serum levels of protein CCL15	2
Serum levels of protein CXCL5	2
Serum levels of protein FASLG	2
Serum levels of protein FGF19	2
Serum levels of protein HBEGF	2
Serum levels of protein LHCGR	2
Serum levels of protein NRP1	2
Serum levels of protein PAM	2
Serum levels of protein PRDM1	2
Serum levels of protein REG1A	2
Serum levels of protein SMPD1	2
Serum levels of protein TMPRSS11D	2
Serum levels of protein TXNDC12	2
Serum levels of protein VEGFA	2
Serum omega-3 polyunsaturated fatty acid concentration in metabolic syndrome	2
Serum omega-6 to omega-3 polyunsaturated fatty acid ratio in metabolic syndrome	2
Serum uric acid levels in response to allopurinol in gout	2
Severity of nausea and vomiting of pregnancy	2
Sleep duration (oversleepers vs undersleepers)	2
Small vessel stroke (CCSp classification)	2
Smoking intensity (cotinine levels/cigarettes per day)	2
Sodium levels	2
Spermidine levels	2
Spherical equivalent (joint analysis main effects and education interaction)	2
Sphingomyelin (d18:0/16:0) levels	2
Sphingomyelin (d18:1/18:1, d18:2/18:0) levels	2
Sphingomyelin (d18:1/20:1, d18:2/20:0) levels	2
Sphingomyelin (d18:2/16:0) levels	2
Sphingomyelin (d18:2/18:0) levels	2
Sphingomyelin (d18:2/20:0) levels	2
Sphingomyelin (d18:2/24:1, d18:1/24:2) levels	2
Sphingomyelin_35:1_[M+H]1+ levels	2
Sphingomyelin_42:1_[M+H]1+ levels	2
Sphingomyelin_42:2_[M+OAc]1- levels	2
Sphingomyelin(33:1)_[M-CH3]1- levels	2
Sphingomyeline C16:1 levels	2
Sphingomyeline C18:1 levels	2
Sphingomyeline C20:2 levels	2
Sphingomyeline C24:0 levels	2
Sphingomyeline C24:1 levels	2
Spine bone size	2
Sporadic neuroblastoma	2
Stearic acid (18:0) levels	2
Stearidonate (18:4n3) levels	2
Stearoyl-arachidonoyl-glycerol (18:0/20:4) [1] levels	2
Stearoyl-arachidonoyl-glycerol (18:0/20:4) [1] levels in elite athletes	2
Stem cell factor levels	2
Subarachnoid hemorrhage	2
Suicide attempt	2
Systemic lupus erythematosus and Systemic sclerosis	2
Systemic sclerosis	2
T cell lymphocyte profile difference	2
Theobromine levels	2
Theophylline levels	2
Threonine levels	2
Thyroid hormone levels	2
Thyroid peroxidase antibody positivity	2
Total body bone mineral density	2
Total Lysophosphatidylcholine levels	2
Total Phosphatidylethanolamine levels	2
Total Phosphatidylinositol levels	2
Total Trihexosylcermide levels	2
Triacylglycerol (48:2) [NL-16:0] levels	2
Triacylglycerol (54:3) [NL-18:1] levels	2
Triacylglycerol 54:9 levels	2
Triacylglycerol 56:10 levels	2
Triacylglycerol 56:9 levels	2
Triacylglycerol_48:4_[M+NH4]1+ levels	2
Triacylglycerol_50:2_[M+NH4]1+ levels	2
Triacylglycerol_50:5_[M+NH4]1+ levels	2
Triglycerides (58:9) levels	2
Triglycerides-Blood Pressure (TG-BP)	2
Trihexosylcermide (d18:1/16:0) levels	2
Trihexosylcermide (d18:1/22:0) levels	2
Trihexosylcermide (d18:1/24:1) levels	2
Two-hour glucose	2
Two-hour glucose challenge	2
Ulcerative colitis vs rheumatoid arthritis (ordinary least squares (OLS))	2
Urinary albumin-to-creatinine ratio in diabetes	2
Urinary sodium to creatinine ratio	2
Urinary sodium to potassium ratio	2
Vascular endothelial growth factor A levels	2
Venous thromboembolism or von Willebrand factor levels (pleiotropy)	2
Verbal memory performance (immediate recall change)	2
Vitamin B12 levels	2
Vitamin C levels	2
Waist circumference adjusted for BMI in smokers	2
Wellbeing index	2
X-12216 levels	2
X-19438 levels	2
X-21286 levels	2
X-24295 levels	2
Yeast infection	2
1-methylnicotinamide levels	1
1-methylnicotinamide levels in elite athletes	1
1,5-anhydroglucitol (1,5-ag) levels	1
2-methylmalonylcarnitine (C4-DC) levels	1
3-bromo-5-chloro-2,6-dihydroxybenzoic acid levels	1
3-hydroxy-1-methylpropylmercapturic acid levels in smokers	1
3-phenylpropionate (hydrocinnamate) levels in elite athletes	1
3beta,7alpha-dihydroxy-5-cholestenoate levels	1
4-allylphenol sulfate levels in elite athletes	1
4-hydroxychlorothalonil levels	1
4-hydroxyphenylacetylglutamine levels in elite athletes	1
5alpha-androstan-3alpha,17beta-diol monosulfate (1) levels in elite athletes	1
Abdominal aortic calcification levels	1
Ability to confide in someone	1
ABO blood group (AB vs non-AB)	1
ABO blood group (B vs O)	1
ABO blood group (O vs non-O)	1
Accelerometer measured moderate to vigorous physical activity	1
Acceptance of an invitation to wear a physical activity monitor	1
Actinic keratosis	1
Actinobacteria abundance in stool	1
Actinobacteriota abundance in stool	1
Actinomycetales abundance in stool	1
Acute graft versus host disease in bone marrow transplantation (donor effect)	1
Acylcarnitine (16:0) levels	1
Acylcarnitine (16:1) levels	1
Acylcarnitine (17:0) (b) levels	1
Acylcarnitine (18:1) levels	1
Acylcarnitine (18:2) levels	1
Addison's disease	1
ADHD vs Tourette's syndrome and other tic disorders (ordinary least squares (OLS))	1
Adiponectin levels	1
Adult asthma	1
Affective disorder and suicide attempts	1
Age at voice drop	1
Age-related diseases and mortality	1
Age-related hearing impairment	1
Airway imaging phenotypes	1
Alcohol and nicotine co-dependence	1
Alcohol consumption over the past year	1
Alcohol dependence (age at onset)	1
Alcohol dependence (desire to cut drinking)	1
Alcohol dependence (tolerance)	1
Alcohol dependence symptom count	1
Alkaline phosphatase (UKB data field 30610)	1
Alkenylphosphatidylcholine (P-16:0/18:2) levels	1
Alkenylphosphatidylcholine (P-18:0/18:2) levels	1
Alkenylphosphatidylethanolamine (P-16:0/20:3) (b) levels	1
Alkenylphosphatidylethanolamine (P-17:0/22:6) (a) levels	1
Alkenylphosphatidylethanolamine (P-18:0/20:3) (a) levels	1
Alkenylphosphatidylethanolamine (P-18:0/20:3) (b) levels	1
Alkenylphosphatidylethanolamine (P-18:0/20:5) levels	1
Alkenylphosphatidylethanolamine (P-18:0/22:5) (n3) levels	1
Alkenylphosphatidylethanolamine (P-18:0/22:6) levels	1
Alkyldiacylglycerol (O-50:1) [NL-16:0] levels	1
Alkyldiacylglycerol (O-52:0) [NL-16:0] levels	1
Alkyldiacylglycerol (O-52:2) [NL-16:0] levels	1
Alkylphosphatidylcholine (O-18:0/22:6) levels	1
Allergic disease (asthma, hay fever and/or eczema) (age of onset)	1
Allergic disease (asthma, hay fever and/or eczema) (multivariate analysis)	1
Allergy	1
Alopecia areata	1
Alzheimer's disease or LDL levels (pleiotropy)	1
Amyotrophic lateral sclerosis (sporadic)	1
Androstenediol (3beta,17beta) monosulfate (1) levels in elite athletes	1
Androsterone sulfate levels	1
Androsterone sulfate levels in elite athletes	1
Ankle-brachial index	1
Anorexia nervosa or obsessive-compulsive disorder	1
Anorexia nervosa vs autism spectrum disorder (ordinary least squares (OLS))	1
Anti-JC polyomavirus IgG seropositivity	1
Anti-measles virus IgG levels	1
Anti-polyomavirus 2 IgG seropositivity	1
Antipsychotic drug-induced weight gain	1
Anxiety and stress-related disorders	1
Aortic aneurysm	1
Aortic root size	1
aparc-a2009s rh area G-occipital-sup	1
aparc-a2009s rh volume G-occipital-sup	1
aparc-a2009s rh volume S-collat-transv-ant	1
aparc-a2009s rh volume S-oc-temp-med+Lingual	1
aparc-DKTatlas rh area insula	1
Apples liking	1
Arterial stiffness index	1
Arthritis (juvenile idiopathic)	1
Ascending aorta diameter	1
aseg lh volume Hippocampus	1
aseg rh volume Hippocampus	1
Asparaginase hypersensitivity in acute lymphoblastic leukemia	1
Asthma (age of onset)	1
Asthma (moderate or severe)	1
Asthma and attention deficit hyperactivity disorder	1
Asthma or allergic disease (pleiotropy)	1
Asthma-COPD overlap syndrome	1
Asymptomatic hyperuricaemia (age <50)	1
Asymptomatic hyperuricaemia (age >=50)	1
Attention deficit hyperactivity disorder (childhood)	1
Attention deficit hyperactivity disorder (late-diagnosed)	1
Attention deficit hyperactivity disorder or caudate nucleus volume (pleiotropy)	1
Autoimmune hepatitis type-1	1
Bacilli A abundance in stool	1
Barrett's esophagus or esophageal adenocarcinoma x sex interaction (2df test)	1
Basal Cell Adhesion Molecule levels	1
Beetroot liking	1
Beta 1 electroencephalogram power	1
Beta-2 microglubulin plasma levels	1
Beta-endorphin levels	1
Bifidobacteriaceae abundance in stool	1
Bifidobacterium abundance in stool	1
Bifidobacterium adolescentis abundance in stool	1
Bifidobacterium angulatum abundance in stool	1
Bifidobacterium bifidum abundance in stool	1
Bifidobacterium breve abundance in stool	1
Bifidobacterium catenulatum abundance in stool	1
Bifidobacterium infantis abundance in stool	1
Bifidobacterium kashiwanohense abundance in stool	1
Bifidobacterium longum abundance in stool	1
Bifidobacterium pseudocatenulatum abundance in stool	1
Bifidobacterium ruminantium abundance in stool	1
Bilateral cleft lip and palate	1
Biological age (BioAge)	1
Bipolar disorder (early vs late onset)	1
Bipolar disorder lithium response (categorical) or schizophrenia	1
Bipolar disorder lithium response (continuous) or schizophrenia	1
Bipolar disorder vs anorexia nervosa (ordinary least squares (OLS))	1
Birth year infant mortality rates	1
Bitter taste perception (6-n-propylthiouracil) in obesity with metabolic syndrome	1
Bitter taste perception (phenylthiocarbamide) in obesity with metabolic syndrome	1
Bitter taste response	1
Blond vs. brown/black hair color	1
Blood trace element (Zn levels)	1
BMI at 3 months old	1
BMI at 6 months old	1
BMI at 8 months old	1
BMI at birth	1
Body mass index (change over time) in cancer	1
Body mass index (change over time) in cancer or chronic obstructive pulmonary disease	1
Bone mineral density (hip)	1
Bone mineral density (spine)	1
Bone stiffness index	1
Brain functional connectivity measurement (characteristic path length)	1
Brain functional connectivity measurement (global efficiency)	1
Brain functional connectivity measurement (strength limbic)	1
Brain functional connectivity measurement (strength salience)	1
Brain functional connectivity measurement (strength somatomotor)	1
Brain rsFMRI measurement (amplitude of low frequency fluctations) (Net100_Node30)	1
Brain rsFMRI measurement (functional connectivity) (Net_Edge_ICA3)	1
Brain rsFMRI measurement (functional connectivity) (Net100_Pair11_42)	1
Brain rsFMRI measurement (functional connectivity) (Net100_Pair13_29)	1
Brain rsFMRI measurement (functional connectivity) (Net100_Pair2_15)	1
Brain rsFMRI measurement (functional connectivity) (Net100_Pair2_29)	1
Brain rsFMRI measurement (functional connectivity) (Net100_Pair21_49)	1
Brain rsFMRI measurement (functional connectivity) (Net100_Pair29_44)	1
Brain rsFMRI measurement (functional connectivity) (Net100_Pair30_41)	1
Brain rsFMRI measurement (functional connectivity) (Net100_Pair34_48)	1
Brain rsFMRI measurement (functional connectivity) (Net100_Pair5_21)	1
Brain rsFMRI measurement (functional connectivity) (Net100_Pair7_11)	1
Brain rsFMRI measurement (functional connectivity) (Net100_Pair9_29)	1
Brain rsFMRI measurement (functional connectivity) (Net25_Pair10_11)	1
Brain rsFMRI measurement (functional connectivity) (Net25_Pair10_12)	1
Brain rsFMRI measurement (functional connectivity) (Net25_Pair11_12)	1
Brain rsFMRI measurement (functional connectivity) (Net25_Pair12_17)	1
Brain shape (segment 120)	1
Brain shape (segment 122)	1
Brain shape (segment 42)	1
Brain shape (segment 7)	1
Brain shape (segment 80)	1
Bread type: White (UKB data field 1448_1)	1
Bread type: Wholemeal/wholegrain vs white and brown (UKB data field 1448)	1
Brevibacillaceae abundance in stool	1
Brevibacillales abundance in stool	1
Brugada syndrome	1
C-C motif chemokine 15 levels	1
C-C motif chemokine 3 levels	1
C-X-C motif chemokine 16 levels	1
CAG-81 sp000435795 abundance in stool	1
Cardioembolic stroke (CCS and TOAST classification)	1
Cardiorespiratory fitness slope	1
Cardiovascular risk factors	1
Carotid intima media thickness (mean-maximum)	1
Carotid plaque	1
Carotid plaque burden	1
Cathepsin F levels	1
Cathepsin H levels	1
Caudate volume change rate x age interaction (1df)	1
CCL25 levels	1
CD16-CD56 on Natural Killer	1
CD209 antigen levels	1
CD4 on naive CD4+ T cell	1
CD4+ T cell Absolute Count	1
CD45RA- CD4+ T cell Absolute Count	1
CD64 on CD14+ CD16+ monocyte	1
Celiac disease and Rheumatoid arthritis	1
Celiac disease or Rheumatoid arthritis	1
Central Memory CD4+ T cell Absolute Count	1
Cereal type: Biscuit cereal (e.g. Weetabix) (UKB data field 1468_2)	1
Cerebral venous thrombosis	1
Cervical artery dissection	1
Childhood asthma with severe exacerbations	1
Childhood onset type 2 diabetes	1
Cholesterol efflux capacity (ABCA-1 dependent assay)	1
Cholesterol efflux capacity (BHK stimulated assay)	1
Cholesterol efflux capacity (cAMP stimulated assay)	1
Cholesteryl ester (18:0) levels	1
Cholesteryl ester_17:0_[M+NH4]1+ levels	1
Cholesteryl ester_18:1_[M+NH4]1+ levels	1
Cholesteryl esters to total lipids ratio in chylomicrons and extremely large VLDL	1
Chronic obstructive pulmonary disease x current smoker interaction (1df)	1
Chronic obstructive pulmonary disease x ever smoker interaction (1df)	1
Cigarettes smoked per day (current)	1
Cigarettes smoked per day in Schizophrenia	1
Circulating fibroblast growth factor 23 levels	1
Circulating levels of total-tau	1
Cis-4-decenoylcarnitine (C10:1) levels in elite athletes	1
Cisplatin-induced ototoxicity	1
Citrulline levels	1
Cleft lip or cleft lip with cleft palate (pleiotropy)	1
Cleft lip with or without cleft palate (maternal periconceptional vitamin use interaction)	1
Clinical laboratory measurements	1
Clozapine-induced cytotoxicity	1
Coagulation factor levels	1
Cocaine dependence	1
Cognitive function (delayed memory) (longitudinal)	1
Combined resilience (covariance of educational attainment with residual cognitive resilience)	1
Common traits (Other)	1
Conduct disorder (maternal expressed emotions interaction)	1
Congenital heart disease (maternal effect)	1
Conotruncal heart defects (maternal effects)	1
Conscientiousness	1
Copine-1 levels	1
Coronary artery disease in diabetes	1
Coronary artery disease in individuals without type 2 diabetes	1
Coronary artery disease in type 1 diabetes	1
Coronary heart disease x type 2 diabetes interaction	1
Cryptic phenotype that captures autosomal dominant polycystic kidney disease severity	1
Cutaneous lupus erythematosus	1
Cutaneous melanoma (MTAG)	1
CXCL5 levels	1
D-dimer levels	1
Decanoylcarnitine (C10) levels in elite athletes	1
Dentate gyrus molecular layer volume	1
Depression (quantitative trait)	1
Depressive symptom (appetite changes) (binary trait)	1
Depressive symptom (fatigue) (ordinal trait)	1
Depressive symptom (low self-esteem) (ordinal trait)	1
Depressive symptom (sleep problems) (binary trait)	1
Depressive symptoms (binary sum-score)	1
Depressive symptoms (sum-score)	1
Descending aorta distensibility (MTAG)	1
Descending aorta maximum area	1
Descending aorta maximum area (MTAG)	1
Diacylglycerol_36:5_[M+H-H2O]1+ levels	1
diarrhoeal disease at age 1	1
diarrhoeal disease at age 1 with doctor diagnosis	1
diarrhoeal disease at age 2 with doctor diagnosis	1
Diastolic blood pressure (baseline)	1
Differentiated thyroid cancer	1
Diffuse cutaneous systemic sclerosis	1
Disrupted circadian rhythm (low relative amplitude of rest-activity cycles)	1
Disruptive behavior disorder and attention deficit hyperactivity disorder	1
Distal colorectal cancer	1
Distal/Left-sided colorectal cancer	1
Drug-induced liver injury (flucloxacillin)	1
Drusen volume within a central 3 mm circle (model 2)	1
Drusen volume within a central 5 mm circle (model 2)	1
Duodenal ulcer	1
E Cad plasma levels	1
Early cardiac repolarization	1
Eating disorders	1
Electrocardiographic conduction measures	1
Electrodermal activity	1
Electroencephalographic traits in alcoholism	1
Emphysema imaging phenotypes	1
End-stage knee osteoarthritis	1
Endometrial cancer	1
Endometrial cancer (endometrioid histology)	1
Eosinophilic esophagitis	1
Eosinophilic esophagitis (pediatric)	1
Epiandrosterone sulfate levels	1
Epiandrosterone sulfate levels in elite athletes	1
Esterified stigmasterol	1
Executive function	1
Exercise treadmill test traits	1
Externalizing behaviour score	1
F-burn/spicy liking (derived food-liking factor)	1
F-strong alcohol liking (derived food-liking factor)	1
Facial morphology (factor 21, depth of nasal alae)	1
Faecalicatena lactaris abundance in stool	1
Familial squamous cell lung carcinoma	1
FAS plasma levels	1
Fasting triglycerides levels in very large VLDL	1
Fasting very large VLDL particle concentration	1
Fatty acids (20:3)W6 levels	1
Febrile seizures (MMR vaccine-related)	1
Femoral neck size	1
Fibroblast growth factor 19 levels	1
Fibroblast growth factor 23 levels	1
Follicle stimulating hormone in healthy women	1
Gait speed in old age	1
Galactonate levels	1
Galectin-3 levels	1
Gamma-glutamylthreonine levels in elite athletes	1
Gastric parietal cell autoantibody levels in type 1 diabetes	1
Gemcitabine-induced early high-grade neutropenia in pancreatic cancer	1
Gestational age at birth (child effect)	1
Glaucoma (multi-trait analysis)	1
Global electrical heterogeneity phenotypes	1
Globe artichoke liking	1
GM3 ganglioside (d18:1/16:0) levels	1
GM3 ganglioside (d18:1/22:0) levels	1
GM3 ganglioside (d18:1/24:0) levels	1
GM3 ganglioside (d18:1/24:1) levels	1
Gout (normal type)	1
Gout in chronic kidney disease	1
Gut microbiota abundance (family Streptococcaceae id.1850)	1
Gut microbiota abundance (genus Ruminococcus torques group id.14377)	1
Gut microbiota abundance (k_Bacteria.p_Actinobacteria.c_Actinobacteria.o_Bifidobacteriales.f_Bifidobacteriaceae.g_Bifidobacterium.s_Bifidobacterium_adolescentis)	1
Gut microbiota abundance (k_Bacteria.p_Actinobacteria.c_Actinobacteria.o_Bifidobacteriales.f_Bifidobacteriaceae.g_Bifidobacterium.s_Bifidobacterium_bifidum)	1
Gut microbiota abundance (k_Bacteria.p_Actinobacteria.c_Actinobacteria.o_Bifidobacteriales.f_Bifidobacteriaceae.g_Bifidobacterium.s_Bifidobacterium_longum)	1
Gut microbiota abundance (k_Bacteria.p_Actinobacteria.c_Actinobacteria.o_Bifidobacteriales.f_Bifidobacteriaceae.g_Bifidobacterium)	1
Gut microbiota abundance (k_Bacteria.p_Actinobacteria.c_Actinobacteria.o_Bifidobacteriales.f_Bifidobacteriaceae)	1
Gut microbiota abundance (k_Bacteria.p_Actinobacteria.c_Actinobacteria.o_Bifidobacteriales)	1
Gut microbiota abundance (k_Bacteria.p_Actinobacteria.c_Actinobacteria)	1
Gut microbiota abundance (k_Bacteria.p_Actinobacteria)	1
Gut microbiota presence (family Pseudomonadaceae id.3718)	1
Gut microbiota relative abundance (Dorea)	1
Gut microbiota relative abundance (unclassified genus belonging to family Clostridiaceae)	1
Haloplasmatales abundance in stool	1
Handedness (Right-handed vs. non-right-handed)	1
Haptoglobin levels	1
Hashimoto thyroiditis	1
HDL cholesterol levels in HIV infection	1
Healthspan	1
Hematological parameters	1
Hepatocyte growth factor activator levels	1
High IL-1beta levels in gingival crevicular fluid	1
Hip bone size	1
Hippocampal tail volume	1
Hippocampal volume in Alzheimer's disease dementia	1
HippSubfield lh volume CA4-body	1
HippSubfield lh volume GC-ML-DG-body	1
HippSubfield lh volume Hippocampal-tail	1
HippSubfield lh volume Whole-hippocampal-body	1
HippSubfield lh volume Whole-hippocampus	1
HippSubfield rh volume CA4-body	1
HippSubfield rh volume GC-ML-DG-body	1
HippSubfield rh volume Hippocampal-tail	1
HippSubfield rh volume subiculum-body	1
HippSubfield rh volume Whole-hippocampal-body	1
HippSubfield rh volume Whole-hippocampal-head	1
HIV-1 viral setpoint	1
Hodgkin's lymphoma	1
Holdemania sp900120005 abundance in stool	1
HTLV-1 associated myelopathy	1
Human milk oligosaccharide concentration (difucosyllactose)	1
Human milk oligosaccharide concentration (fucodisialyllacto-N-hexaose)	1
Human milk oligosaccharide concentration (lacto-N-fucopentaose I)	1
Human milk oligosaccharide concentration (lacto-N-fucopentaose II)	1
Human milk oligosaccharide concentration (lacto-N-tetrose)	1
Human milk oligosaccharide concentration (sialyl-lacto-N-tetraose b)	1
Hydroxysphingomyeline C16:1 levels	1
Hydroxysphingomyeline C22:1 levels	1
Ideal cardiovascular health (clinical and behavioral)	1
Ideal cardiovascular health (clinical)	1
Idiopathic achalasia	1
IDP dMRI ProbtrackX ICVF atr r	1
IDP dMRI ProbtrackX L3 fmi	1
IDP dMRI ProbtrackX MD fmi	1
IDP dMRI TBSS ICVF Posterior corona radiata L	1
IDP dMRI TBSS ICVF Posterior thalamic radiation R	1
IDP dMRI TBSS OD Posterior corona radiata R	1
IDP T1 FAST ROIs L hippocampus	1
IDP T1 FAST ROIs R hippocampus	1
IDP T1 FIRST left pallidum volume	1
Immune reponse to smallpox (secreted IL-2)	1
Indolepropionate levels	1
Inflammatory biomarkers	1
Initial pursuit acceleration	1
Insulin disposition index	1
Insulin levels	1
Insulin-like growth factors	1
Interleukin-27 levels	1
Intertrochanteric region size	1
Intestinal permeability measurement	1
Intracerebral hemorrhage	1
Ischemic stroke (large artery atherosclerosis)	1
Ischemic stroke (small artery occlusion)	1
Ischemic stroke (small-vessel)	1
Itch intensity from mosquito bite	1
JC polyomavirus VP1 antibody levels	1
Juvenile idiopathic arthritis (oligoarticular or rheumatoid factor-negative polyarticular)	1
Juvenile myoclonic epilepsy	1
Keratinocyte cancer (MTAG)	1
Keratoconus	1
Kiwi liking	1
Knee pain	1
Kynurenine levels	1
Lachnospira rogosae abundance in stool	1
Lactobacillus B abundance in stool	1
Lactobacillus B ruminis abundance in stool	1
Large artery stroke (MTAG)	1
Latent autoimmune diabetes vs. type 2 diabetes	1
Left unilateral cleft lip	1
Left ventricle diastolic internal dimension	1
Left ventricular end-systolic volume	1
Leuconostoc abundance in stool	1
Leuconostoc mesenteroides abundance in stool	1
Leukocyte telomere length	1
Light-intensity physical activity duration	1
Lipid or lipoprotein levels	1
Lipid traits (pleiotropy) (HIPO component 1)	1
Lipoprotein phospholipase A2 activity in cardiovascular disease	1
Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease	1
Lipoprotein-associated phospholipase A2 activity change in response to statin therapy	1
Lipoprotein(a) levels adjusted for apolipoprotein(a) isoforms	1
Lithostathine-1-alpha levels	1
Lobe attachment (rater-scored or self-reported)	1
Low density lipoprotein cholesterol levels (on statin treatment)	1
Low myopia	1
Lung function (FEV1) and waist to hip ratio adjusted for BMI	1
Lung function (FVC) and waist to hip ratio adjusted for BMI	1
Lung function (low FEV1 vs high FEV1)	1
Lung volume	1
Lymphocyte Absolute Count	1
Lysoalkenylphosphatidylethanolamine (P-18:0) levels	1
Major depression and alcohol dependence	1
Major depressive disorder in trauma exposed individuals	1
Major depressive disorder vs ADHD (ordinary least squares (OLS))	1
Major depressive disorder vs anorexia nervosa (ordinary least squares (OLS))	1
Major depressive disorder vs autism spectrum disorder (ordinary least squares (OLS))	1
Malaria	1
Male puberty timing (early vs. average onset voice breaking)	1
Mannose-binding protein C levels	1
Maternal nondisjunction of chromosome 21 (MI error vs fathers)	1
Matrix metalloproteinase-10 levels	1
Mean diameter of VLDL particles	1
Medial thalamic nuclei volume	1
Medication use (drugs for peptic ulcer and gastro-oesophageal reflux disease)	1
Metabolic syndrome (bivariate traits)	1
Metabolite peak levels (QI15502)	1
Migraine and/or diastolic blood pressure	1
Minimum ankle–brachial index	1
Mitochondrial heteroplasmy measurement	1
Mitogen-activated protein kinase 3 levels	1
Mitral valve prolapse after mitral valve surgery	1
Monocyte chemoattractant protein-3 levels	1
Monokine induced by gamma interferon levels	1
Mumps	1
Myeloproliferative neoplasms	1
Myo-inositol levels in elite athletes	1
Myocardial infarction (early onset)	1
Myopia (pathological)	1
N-acetyl neuraminic acid levels	1
N-acetylleucine levels in elite athletes	1
N-acetylvaline levels in elite athletes	1
N1-methyl-2-pyridone-5-carboxamide levels	1
N6-acetyllysine levels in elite athletes	1
Nasopharyngeal carcinoma (SNP x SNP interaction)	1
Negativibacillus abundance in stool	1
Negativibacillus sp000435195 abundance in stool	1
Neuroblastoma or malignant cutaneous melanoma	1
Neuropathic pain in type 2 diabetes	1
New onset hypertension	1
Nicotine dependence symptom count	1
Night sleep phenotypes	1
Non-glioblastoma glioma	1
Nonatopic asthma and/or BMI	1
Nose size	1
Number of children	1
Number of common colds	1
Number of pregnancies	1
O-sulfo-L-tyrosine levels in elite athletes	1
Octanoylcarnitine (C8) levels in elite athletes	1
Ocular disease	1
Odorant perception (&beta;-ionone)	1
Oleoyl-oleoyl-glycerol (18:1/18:1) [2] levels in elite athletes	1
Oral cavity cancer	1
Oranges liking	1
Ornithine levels	1
Oropharynx cancer	1
Oropharynx cancer and human papilloma virus 16 negative oropharyngeal cancer	1
Osteoporosis	1
OTU97_27 (Bacteroides) prevalence	1
OTU97_4 (Alistipes) abundance	1
Palmitoyl-linoleoyl-glycerol (16:0/18:2) [2] levels in elite athletes	1
Pantothenate levels	1
Parasitemia in Tripanosoma cruzi seropositivity	1
Parkinson's disease (motor and cognition)	1
Perinatal depression	1
Periodontal microbiota	1
Peripheral arterial disease (traffic-related air pollution interaction)	1
Peripheral blood CD34+ cell levels	1
Periventricular white matter hyperintensities	1
Phenylalanine levels	1
Phocea abundance in stool	1
Phocea massiliensis abundance in stool	1
Phosphatidylcholines (36:3E)1 levels	1
Phosphatidylcholines (40:5)A levels	1
Physical activity (Relative amplitude)	1
Physical activity (Total log acceleration 6pm-8pm)	1
Physical aggression in schizophrenia	1
Phytosterol levels	1
Plasma anti-thyroglobulin levels	1
Plasma kynurenine levels in major depressive disorder	1
Plasmacytoid Dendritic Cell Absolute Count	1
Platelet reactivity measurement (collagen-ADP)	1
Postoperative venous thromboembolism	1
Pre-treatment viral load in HIV-1 infection	1
Principal component-derived dietary pattern 11	1
Principal component-derived dietary pattern 19	1
Principal component-derived dietary pattern 20	1
Protein biomarker	1
Psoriatic arthritis	1
Pulmonary function	1
Pulse rate	1
QRS complex (Cornell)	1
Radiation response	1
Red wine consumption (glasses per month) (UKB data field 1578, 4419)	1
Residual cognitive resilience	1
Response to allopurinol in gout (change in serum uric acid levels)	1
Response to amphetamines	1
Response to angiotensin II receptor blocker therapy	1
Response to antipsychotic treatment	1
Response to paliperidone in schizophrenia (Multivariate)	1
Response to statins (LDL cholesterol percent change)	1
Response to taxane treatment (placlitaxel)	1
Response to zileuton treatment in asthma (FEV1 change interaction)	1
rfMRI amplitudes (ICA100 node 30)	1
rfMRI amplitudes (ICA25 node 12)	1
rfMRI connectivity (ICA100 edge 1001)	1
rfMRI connectivity (ICA100 edge 1011)	1
rfMRI connectivity (ICA100 edge 1083)	1
rfMRI connectivity (ICA100 edge 1090)	1
rfMRI connectivity (ICA100 edge 1091)	1
rfMRI connectivity (ICA100 edge 1099)	1
rfMRI connectivity (ICA100 edge 237)	1
rfMRI connectivity (ICA100 edge 380)	1
rfMRI connectivity (ICA100 edge 383)	1
rfMRI connectivity (ICA100 edge 387)	1
rfMRI connectivity (ICA100 edge 39)	1
rfMRI connectivity (ICA100 edge 391)	1
rfMRI connectivity (ICA100 edge 399)	1
rfMRI connectivity (ICA100 edge 414)	1
rfMRI connectivity (ICA100 edge 429)	1
rfMRI connectivity (ICA100 edge 43)	1
rfMRI connectivity (ICA100 edge 464)	1
rfMRI connectivity (ICA100 edge 471)	1
rfMRI connectivity (ICA100 edge 485)	1
rfMRI connectivity (ICA100 edge 488)	1
rfMRI connectivity (ICA100 edge 495)	1
rfMRI connectivity (ICA100 edge 52)	1
rfMRI connectivity (ICA100 edge 605)	1
rfMRI connectivity (ICA100 edge 659)	1
rfMRI connectivity (ICA100 edge 810)	1
rfMRI connectivity (ICA100 edge 995)	1
rfMRI connectivity (ICA25 edge 132)	1
rfMRI connectivity (ICA25 edge 65)	1
rfMRI connectivity ICA-features 1	1
rfMRI connectivity ICA-features 3	1
Right lateral prefrontal cortical growth	1
Right ventricular end diastolic volume	1
RR interval (heart rate)	1
Salmon liking	1
Schizophrenia, schizoaffective disorder or bipolar disorder	1
Self-rated health	1
Serum 25-Hydroxyvitamin D level variance	1
Serum cancer antigen 19.9 levels	1
Serum carcinoembryonic antigen levels	1
Serum levels of protein APBB2	1
Serum levels of protein BPIFA2	1
Serum levels of protein BTNL8	1
Serum levels of protein C6orf58	1
Serum levels of protein CASC4	1
Serum levels of protein CCL25	1
Serum levels of protein CCL28	1
Serum levels of protein CD200R1L	1
Serum levels of protein CEP57	1
Serum levels of protein CHST15	1
Serum levels of protein CSGALNACT2	1
Serum levels of protein CTSF	1
Serum levels of protein CXCL11	1
Serum levels of protein DEFB119	1
Serum levels of protein F8	1
Serum levels of protein FAM177A1	1
Serum levels of protein FAM3B	1
Serum levels of protein FAM3D	1
Serum levels of protein FUT3	1
Serum levels of protein GKN2	1
Serum levels of protein GNS	1
Serum levels of protein GOLM1	1
Serum levels of protein ICAM2	1
Serum levels of protein IFI16	1
Serum levels of protein IGF1	1
Serum levels of protein KIN	1
Serum levels of protein KLRC3	1
Serum levels of protein KMT2C	1
Serum levels of protein LCT	1
Serum levels of protein LPO	1
Serum levels of protein LRP1B	1
Serum levels of protein LRRC32	1
Serum levels of protein MANF	1
Serum levels of protein MAPK8	1
Serum levels of protein MBL2	1
Serum levels of protein NADK	1
Serum levels of protein NCAM1	1
Serum levels of protein PIP	1
Serum levels of protein PNLIPRP2	1
Serum levels of protein PNPLA2	1
Serum levels of protein PRDX6	1
Serum levels of protein PRG3	1
Serum levels of protein SECTM1	1
Serum levels of protein SHANK3	1
Serum levels of protein SUMF1	1
Serum levels of protein TBCA	1
Serum levels of protein TCN1	1
Serum levels of protein THPO	1
Serum levels of protein VIMP	1
Serum lipase activity	1
Serum thyroid-stimulating hormone levels	1
Serum urate levels	1
Serum zinc levels	1
Severe COVID-19 infection with respiratory failure (analysis I)	1
Severe COVID-19 infection with respiratory failure (analysis II)	1
Sexual dysfunction (SSRI/SNRI-related)	1
Sexual orientation	1
Sib-shared facial trait 399; Facial segment 11; 3D morphology of the nose	1
Sib-shared facial trait 828; Facial segment 45; 3D morphology of the nose alae	1
Sib-shared facial trait 976; Facial segment 60; 3D morphology of the eye sockets	1
Sjögren's syndrome	1
Skin cancer	1
Small vessel stroke (CCS or TOAST classification)	1
Smoking behaviour (age at first cigarette)	1
Smoking initiation (ever vs never)	1
Social autistic-like traits	1
Sonic hedgehog protein levels	1
Sphingolipid d18:1/d18:2 ratio	1
Sphingomyelin(42:0)_[M+OAc]1- levels	1
Spirits liking	1
Spleen iron concentration	1
Spread type: Butter and margarine spreads vs oil-based spreads (UKB data field 1428)	1
Spread type: Flora Pro-Active/Benecol (UKB data field 1428_2)	1
Squamous cell carcinoma	1
SSC-A on CD14+ monocyte	1
SSC-A on monocyte	1
Stroke (ischemic)	1
Subiculum volume	1
Subjective wellbeing conditioned on average household income before tax (multi-trait conditioning and joint analysis)	1
Subjective wellbeing conditioned on cognitive performance (multi-trait conditioning and joint analysis)	1
Subjective wellbeing conditioned on educational attainment (multi-trait conditioning and joint analysis)	1
Subjective wellbeing conditioned on highest math class (multi-trait conditioning and joint analysis)	1
Subjective wellbeing conditioned on self-rated math ability (multi-trait conditioning and joint analysis)	1
Subjective wellbeing conditioned on Townsend deprivation index (multi-trait conditioning and joint analysis)	1
Succinylcarnitine (c4-dc) levels	1
Sudden cardiac arrest in coronary artery disease	1
Suicide attempts	1
Supramarginal gyrus volume	1
Systemic seropositive rheumatic diseases (Systemic sclerosis or systemic lupus erythematosus or rheumatoid arthritis or idiopathic inflammatory myopathies)	1
Systolic blood pressure in sickle cell anemia	1
T cell Absolute Count	1
Tea without sugar liking	1
Telomere length	1
Terrisporobacter othiniensis abundance in stool	1
TestASV_12 (Bacteroides) abundance	1
TestASV_4 (Alistipes) abundance	1
Tetralogy of Fallot	1
Thalamus volume	1
Thrombomodulin levels	1
Thrombosis	1
Thyroid peroxidase antibody levels	1
Tissue factor levels	1
Total Alkenylphosphatidylethanolamine levels	1
Total Alkyldiacylglycerol levels	1
Total cerebellar volume	1
Total cholesterol levels in LDL	1
Total Dehydrocholesteryl ester levels	1
Total GM3 ganglioside levels	1
Total hippocampal volume	1
Total Lysoalkenylphosphatidylethanolamine levels	1
Tourette's syndrome or obsessive-compulsive disorder	1
TRAIL levels	1
Trauma exposure in major depressive disorder	1
Triglycerides to total lipids ratio in chylomicrons and extremely large VLDL	1
Trochanter size	1
Trunk lean mass	1
Tumor necrosis factor levels	1
Tumor necrosis factor receptor 2 levels	1
Turicibacter abundance in stool	1
Turicibacter sp001543345 abundance in stool	1
Turicibacteraceae abundance in stool	1
Type 1 diabetes autoantibodies in high risk HLA genotype individuals (time to event)	1
Type 2 diabetes (time to event)	1
UBA3855 sp900316885 abundance in stool	1
Ubiquitin-like protein ISG15 levels	1
Urinary uric acid excretion	1
Uterine fibroids	1
Vegetable consumption	1
Venous thromboembolism or factor XI levels (pleiotropy)	1
Venous thromboembolism or plasminogen activator inhibitor 1 levels (pleiotropy)	1
Venous thromboembolism or tissue plasminogen activator levels (pleiotropy)	1
Vogt-Koyanagi-Harada syndrome	1
von Willebrand factor levels	1
vWF levels in ischaemic stroke and hyperhomocysteinaemia	1
Waist-to-hip ratio adjusted for BMI x sex interaction	1
Waist-to-hip ratio adjusted for BMI x sex x age interaction (4df test)	1
Warfarin dose variability	1
Whiskey liking	1
White blood cell count (basophil)	1
White blood cell count (eosinophil)	1
White blood cell count (lymphocyte)	1
White blood cell count (neutrophil)	1
White matter lesion progression	1
White matter microstructure (mode of anisotropy)	1
X-11795 levels	1
X-25790 levels	1
